

Verein für  
Association pour le  
Associazione per il



medizinische Qualitätskontrolle  
contrôle de qualité médical  
controllo di qualità medico

# Survey Report

## 2023 - 3

### Survey Specimens

The homogeneity and stability of all specimens were checked before and/or during shipment and no irregularities were noted. The suitability tests were performed by the laboratories of the Universitätsspital Zürich (University Hospital Zurich) (<http://www.uzl.usz.ch/>).

The following survey specimens were produced specifically for MQ by a sub-contractor:  
B2 Uricult, H4 Parasitic Hematology, K14 tumor marker

### Determination of target values

For each target value, the type of determination per ISO17043: 2010 B2.1 is indicated (column "type"):

- a Value known due to production.
- b Certified reference value for use with special specimens
- c Reference value determined by analysis
- d Consensus values of expert laboratories
- e Consensus values of the participants

For methods groups with more than 9 participants, consensus values of the participants ("e") are generally determined.

In order to calculate the target values, we use the mean value of the method group. Values that differ more than 1.5 times the QUALAB-tolerance are outliers and are not used to calculate the target value. Starting point for the elimination of outliers are the values of our suitability tests.

In order to provide all participants with target values that are as meaningful as possible, other methods may also be applied for smaller method groups.

### Uncertainty of the determined target values

The standard uncertainty ( $u_x$ ) is calculated using the following formula (ISO13528):

$$u_x = (\text{target value}/100) * (1.25/\text{square root of "number of participants"}) * \%CV$$

- $u_x$  has the same unit as the target value
- $u_x$  can be compared with the standard deviation of the participants' collective ( $SD = \text{target value} * \%CV / 100$ )
- For participant numbers >18, the standard uncertainty ( $u_x$ ) is significantly lower than the scatter of the collective participants and can be neglected.


### QUALAB and MQ tolerances

For all mandatory analyzes, QUALAB tolerances are used ([www.qualab.ch](http://www.qualab.ch), external quality control). For non-mandatory analyzes, the tolerances are specified by MQ's survey specimen leader.

If the determined uncertainty,  $u_x$ , of the target value is greater than 15% of the QUALAB or MQ tolerance, the letter indicating the type of target detection is marked with an additional star (example "e\*"). Thereby, we are alerting the participants to the fact that the uncertainty of the target value can have an impact on the evaluation.

### Graphics

The results are shown graphically as follows:



### Comparison of Devices

The data in this report allows you to compare the performance of different devices. However, remember to consider the following:


- The chemical control K1 is a ready-to-use commercial control serum. Even if the specimen is of human origin, it is possible that matrix effects occur. These are device-specific and result in different target values.
- Only one specimen was measured. Since the scatter of the results is dependent on the nature of the specimen (matrix effects) and on the signal strength, the determined coefficient of variations (CV in %) cannot be applied generally.
- A large number of runaways is due to administrative errors (wrong unit, results mixed up) or to operator errors (wrong sample, not correctly taken up in solution, not mixed well) and has nothing to do with the type of device.

Zürich, 4.10.2023

Dr. R. Fried  
Survey Director

*Publication of this report or any portion thereof without our prior written consent is not permitted. The original is archived at [www.mqzh.ch](http://www.mqzh.ch)*

# INR




QUALAB tolerance : 15 %

INR ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Innovin	16	87.5	0.0	12.5	1.59	5.2	e
2	Neoplastin R	16	93.7	6.3	0.0	1.66	5.2	e
3	Neoplastin Plus	7	100.0	0.0	0.0	2.04	4.4	e
4	Recombiplastin 2G	11	100.0	0.0	0.0	1.72	5.1	e
5	Other methods	14	100.0	0.0	0.0	1.64	5.3	e

6 additional results were submitted but not published because the method groups were too small. (< results per group)


## Fibrinogen OA



No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Siemens Thrombin	8	100.0	0.0	0.0	1.10	5.2	e*
2	Stago/STA	19	100.0	0.0	0.0	1.14	4.2	e
3	Fibrinogen Q.F.A.	7	100.0	0.0	0.0	1.15	6.3	e*
4	Other methods	5	100.0	0.0	0.0	1.16	5.5	e*

4 additional results were submitted but not published because the method groups were too small. (< results per group)

## Activated Prothrombin Time




QUALAB tolerance : 25 %

Activated Prothrombin Time (Sek)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Actin FS	7	100.0	0.0	0.0	39.9	11.3	e*
2	Pathromtin SL	7	100.0	0.0	0.0	60.3	5.7	e
3	Stago/STA	22	100.0	0.0	0.0	52.0	7.5	e
4	aPTT-SP	7	100.0	0.0	0.0	39.1	6.6	e
5	Other methods	10	100.0	0.0	0.0	39.6	8.7	e

# INR CoaguChek




QUALAB tolerance : 15 %

INR CoaguChek ()

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	CoaguChek Pro II	803	98.7	0.7	0.6	3.0	4.1	e

## Prothrombin time NT



QUALAB tolerance : 15 %

Prothrombin time NT (%)

No. Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1 Innovin	12	91.7	0.0	8.3	99	2.3	e
2 Neoplastin R	14	100.0	0.0	0.0	96	5.0	e
3 Neoplastin Plus	6	100.0	0.0	0.0	93	4.4	e
4 Recombiplastin 2G	10	100.0	0.0	0.0	100	0.3	e
5 Other methods	15	93.3	0.0	6.7	99	2.8	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

## Fibrinogen N



QUALAB tolerance : 15 %


Fibrinogen N (g/l)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Siemens Thrombin	7	100.0	0.0	0.0	2.80	4.6	e
2	Stago/STA	19	100.0	0.0	0.0	2.94	5.0	e
3	Fibrinogen Q.F.A.	10	90.0	0.0	10.0	2.68	4.4	e
4	Fib Clauss (IL)	5	100.0	0.0	0.0	2.61	7.3	e*
5	Other methods	7	100.0	0.0	0.0	2.72	6.9	e*

2 additional results were submitted but not published because the method groups were too small. (< results per group)



## Faktor V




MQ tolerance : 25 %

Faktor V (%)

No. Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1 all Participants	8	100.0	0.0	0.0	97.8	6.0	e

## aPTT N




QUALAB tolerance : 25 %

aPTT N (Sek)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Actin FS	9	100.0	0.0	0.0	22.3	4.6	e
2	Pathromtin SL	5	100.0	0.0	0.0	39.3	9.2	e*
3	Stago/STA	22	100.0	0.0	0.0	31.3	6.4	e
4	aPTT-SP	12	100.0	0.0	0.0	25.3	7.5	e
5	Other methods	7	100.0	0.0	0.0	33.4	13.9	e*

## Faktor VII




MQ tolerance : 25 %

Faktor VII (%)

No. Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1 all Participants	5	100.0	0.0	0.0	102.0	7.1	e*

## Prothrombin time HT




QUALAB tolerance : 15 %

Prothrombin time HT (%)

No. Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1 Innovin	13	100.0	0.0	0.0	99	3.7	e
2 Neoplastin R	13	100.0	0.0	0.0	99	3.3	e
3 Recombiplastin 2G	12	100.0	0.0	0.0	96	5.5	e
4 Other methods	11	90.9	9.1	0.0	98	9.7	e*

4 additional results were submitted but not published because the method groups were too small. (< results per group)

### Anti-FXa (unfrakt-Heparin)




MQ tolerance : 20 %

Anti-FXa (unfrakt-Heparin) (IU/ml)

No. Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1 Stago/STA	9	88.9	0.0	11.1	0.82	7.8	e*
2 ACL	22	100.0	0.0	0.0	0.87	5.4	e
3 Other methods	11	100.0	0.0	0.0	0.89	6.1	e


## Fibrinogen H



No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Siemens Thrombin	4	100.0	0.0	0.0	3.31	2.7	e
2	Stago/STA	15	100.0	0.0	0.0	3.41	2.9	e
3	Fibrinogen Q.F.A.	14	92.9	7.1	0.0	3.33	8.9	e*
4	Other methods	9	100.0	0.0	0.0	3.17	3.2	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

## aPTT H




QUALAB tolerance : 25 %

aPTT H (Sek)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Actin FS	4	100.0	0.0	0.0	116.0	3.2	e
2	Actin FSL	4	100.0	0.0	0.0	108.0	4.6	e
3	Stago/STA	14	100.0	0.0	0.0	120.0	0.0	e
4	aPTT-SP	16	100.0	0.0	0.0	120.0	0.0	e
5	Other methods	5	100.0	0.0	0.0	109.0	5.8	e

One result was submitted but not published because the method group was too small. (< 4 results per group)

## D-dimer



QUALAB tolerance : 21 %


D-dimer (mg/l)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas (Zitratplasma)	7	100.0	0.0	0.0	1.56	9.2	e*
2	STA Liatest	17	100.0	0.0	0.0	1.49	2.6	e
3	Siemens Innovance	12	100.0	0.0	0.0	2.33	5.0	e
4	Pathfast	14	100.0	0.0	0.0	4.95	4.2	e
5	ACL	12	100.0	0.0	0.0	2.12	4.6	e
6	AQT 90 FLEX	6	83.3	16.7	0.0	1.00	11.7	e*
7	VIDAS	17	100.0	0.0	0.0	1.64	5.5	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)



## CoaguChek APTT




QUALAB tolerance : 25 %

CoaguChek APTT (Sek)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	CoaguChek Pro II	7	100.0	0.0	0.0	40.4	2.8	e

### INR CCXS




QUALAB tolerance : 15 %

INR CCXS ()

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	CoaguChek XS	1446	99.3	0.3	0.4	2.9	3.6	e

# INR HC




QUALAB tolerance : 15 %

INR HC ()

No. Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1 Hemochron j.	7	100.0	0.0	0.0	5.4	2.8	e

# INR MI




QUALAB tolerance : 15 %

INR MI ( )

No. Methode	Total	% OK	% insuff.	% outlier	Target	CV% Type
1 MicroINR	123	57.7	13.0	29.3	2.0	10.7 e

# INR Xprecia




QUALAB tolerance : 15 %  
( < 1.3: +/- 0.2 )

INR Xprecia ()

No. Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1 Xprecia	49	87.8	10.2	2.0	1.2	6.9	e

## INR Lumira Dx




QUALAB tolerance : 15 %

INR Lumira Dx ()

No. Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1 Lumira Dx	11	100.0	0.0	0.0	4.5	5.8	e

## Anti-FXa (LMW-Heparin)




MQ tolerance : 20 %

Anti-FXa (LMW-Heparin) (IU/ml)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Stago/STA	9	88.9	0.0	11.1	0.61	7.0	e
2	ACL	15	100.0	0.0	0.0	0.65	8.4	e
3	Other methods	15	100.0	0.0	0.0	0.73	6.7	e

### Anti-FXa (Rivaroxaban)



MQ tolerance : 20 %


Anti-FXa (Rivaroxaban) (µg/l)

No. Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1 Stago/STA	9	100.0	0.0	0.0	73.00	8.0	e*
2 ACL	9	100.0	0.0	0.0	84.70	6.7	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)




## Anti-FXa (Apixaban)



No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ACL	4	100.0	0.0	0.0	81.60	6.3	e*
2	Other methods	4	100.0	0.0	0.0	81.00	9.6	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

### Anti-FXa (Edoxaban)




MQ tolerance : 20 %

Anti-FXa (Edoxaban) (µg/l)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	4	75.0	0.0	25.0	44.00	8.1	e*

# Hemoglobin




QUALAB tolerance : 9 %

Hemoglobin (g/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Automat	9	100.0	0.0	0.0	107.0	2.4	e
2	Cyanmethemoglobin	17	88.2	5.9	5.9	106.8	4.0	e
3	Sysmex X	52	100.0	0.0	0.0	106.8	1.5	e
4	Hemocue	398	94.9	1.8	3.3	106.6	2.6	e
5	Hemocontrol	16	100.0	0.0	0.0	107.7	0.9	e
6	DiaSpect	14	100.0	0.0	0.0	115.4	3.2	e
7	Sysmex	8	100.0	0.0	0.0	106.5	1.1	e

11 additional results were submitted but not published because the method groups were too small. (< results per group)

# Hemoglobin




QUALAB tolerance : 9 %

Hemoglobin (g/l)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex KX21	109	97.2	2.8	0.0	106.6	2.5	e
2	Sysmex Poch - 100i	190	95.7	1.1	3.2	105.6	2.5	e
3	Sysmex XP 300	612	98.2	0.3	1.5	106.1	1.7	e
4	Mythic	237	98.3	1.3	0.4	104.2	2.8	e
5	Sysmex XQ-320	86	98.8	0.0	1.2	107.8	1.1	e
6	Swelab	28	92.8	3.6	3.6	109.2	3.1	e
7	Medonic	5	100.0	0.0	0.0	108.0	2.4	e
8	Celltac Alpha (Nihon	86	98.8	0.0	1.2	109.0	2.2	e
9	Samsung HC10	10	90.0	0.0	10.0	105.9	2.9	e
10	Micros 60	59	98.3	0.0	1.7	105.9	2.7	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

## Hematocrit




QUALAB tolerance : 9 %

Hematocrit (l/l)

No. Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1 Automat	7	85.7	0.0	14.3	0.29	3.4	e*
2 Sysmex X	52	100.0	0.0	0.0	0.31	2.6	e
3 Sysmex	8	100.0	0.0	0.0	0.31	4.0	e*

9 additional results were submitted but not published because the method groups were too small. (< results per group)

## Hematocrit




QUALAB tolerance : 9 %

Hematocrit (l/l)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex XQ-320	87	97.7	0.0	2.3	0.29	2.3	e
2	Sysmex KX21	109	99.1	0.9	0.0	0.29	2.4	e
3	Sysmex PochH - 100i	190	95.2	1.1	3.7	0.31	3.0	e
4	Sysmex XP 300	613	98.0	1.0	1.0	0.29	2.2	e
5	Mythic	237	97.9	2.1	0.0	0.30	3.5	e
6	Swelab	28	92.9	0.0	7.1	0.30	3.1	e
7	Medonic	5	80.0	20.0	0.0	0.30	5.4	e*
8	Celltac Alpha (Nihon	86	84.8	4.7	10.5	0.31	3.7	e
9	Samsung HC10	10	100.0	0.0	0.0	0.32	3.1	e
10	Micros 60	59	94.9	1.7	3.4	0.28	4.0	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

# Erythrocytes




QUALAB tolerance : 25 %

Erythrocytes (T/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Automat	7	100.0	0.0	0.0	3.40	2.4	e
2	Sysmex X	52	100.0	0.0	0.0	3.36	1.6	e
3	Sysmex	8	100.0	0.0	0.0	3.30	1.8	e

7 additional results were submitted but not published because the method groups were too small. (< results per group)

# Erythrocytes



QUALAB tolerance : 25 %


Erythrocytes (T/l)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex XQ-320	87	97.8	1.1	1.1	3.43	3.7	e
2	Sysmex KX21	109	100.0	0.0	0.0	3.39	2.1	e
3	Sysmex Poch - 100i	190	97.4	0.5	2.1	3.47	3.9	e
4	Sysmex XP 300	612	98.9	0.3	0.8	3.38	2.9	e
5	Mythic	236	99.2	0.0	0.8	3.32	3.7	e
6	Swelab	28	96.4	0.0	3.6	3.36	3.6	e
7	Medonic	5	100.0	0.0	0.0	3.39	2.0	e
8	Celltac Alpha (Nihon)	86	100.0	0.0	0.0	3.45	3.1	e
9	Samsung HC10	10	100.0	0.0	0.0	3.43	3.1	e
10	Micros 60	59	96.6	0.0	3.4	3.30	3.8	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)



# Leucocytes




QUALAB tolerance : 25 %

Leucocytes (G/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Automat	6	83.3	16.7	0.0	5.06	12.9	e*
2	Microscopic	5	100.0	0.0	0.0	4.50	12.0	e*
3	Sysmex X	52	100.0	0.0	0.0	5.00	9.3	e
4	Sysmex	8	100.0	0.0	0.0	5.05	7.0	e

7 additional results were submitted but not published because the method groups were too small. (< results per group)

## Leucocytes




QUALAB tolerance : 25 %

Leucocytes (G/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex XQ-320	87	96.6	1.1	2.3	5.26	6.7	e
2	Sysmex KX21	109	97.3	0.9	1.8	5.11	8.1	e
3	Sysmex PochH - 100i	190	96.8	1.1	2.1	4.99	7.4	e
4	Sysmex XP 300	612	99.3	0.2	0.5	5.09	7.0	e
5	Mythic	235	98.2	0.9	0.9	4.98	7.9	e
6	Swelab	28	96.4	3.6	0.0	5.04	9.9	e
7	Medonic	5	100.0	0.0	0.0	5.10	9.0	e*
8	Celltac Alpha (Nihon	86	97.7	0.0	2.3	5.05	6.2	e
9	Samsung HC10	10	80.0	10.0	10.0	5.32	11.2	e*
10	Micros 60	59	96.6	1.7	1.7	4.79	7.8	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

# Thrombocytes




QUALAB tolerance : 25 %

Thrombocytes (G/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Automat	6	100.0	0.0	0.0	190.5	6.9	e
2	Microscopic	4	100.0	0.0	0.0	188.0	5.3	e
3	Sysmex X	52	100.0	0.0	0.0	170.4	3.5	e
4	Sysmex	8	100.0	0.0	0.0	171.0	4.1	e

6 additional results were submitted but not published because the method groups were too small. (< results per group)

# Thrombocytes




QUALAB tolerance : 25 %

Thrombocytes (G/l)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex XQ-320	87	97.8	1.1	1.1	171.0	6.4	e
2	Sysmex KX21	109	98.2	1.8	0.0	174.8	6.6	e
3	Sysmex PochH - 100i	190	97.9	1.6	0.5	175.6	6.5	e
4	Sysmex XP 300	613	99.2	0.3	0.5	177.1	5.4	e
5	Mythic	237	97.9	1.7	0.4	164.1	9.3	e
6	Swelab	28	96.4	3.6	0.0	167.0	10.0	e
7	Medonic	5	100.0	0.0	0.0	166.0	6.0	e
8	Celltac Alpha (Nihon)	86	98.8	1.2	0.0	186.5	7.3	e
9	Samsung HC10	10	100.0	0.0	0.0	183.3	7.7	e
10	Micros 60	59	96.6	1.7	1.7	172.7	10.1	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

## Hemoglobin H2




QUALAB tolerance : 9 %

Hemoglobin H2 (g/l)

No. Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1 Z3	219	96.8	0.0	3.2	94.9	3.1	e
2 Abx Micros	56	96.4	0.0	3.6	95.0	2.9	e
3 Microsemi	887	97.1	0.9	2.0	96.3	2.2	e

## Hematocrit H2




QUALAB tolerance : 9 %

Hematocrit H2 (l/l)

No. Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1 Z3	219	95.9	0.9	3.2	0.27	3.6	e
2 Abx Micros	56	94.6	1.8	3.6	0.25	3.0	e
3 Microsemi	886	96.0	1.7	2.3	0.25	3.0	e

## Leucocytes H2




QUALAB tolerance : 25 %

Leucocytes H2 (G/l)

No. Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1 Z3	219	97.7	0.5	1.8	4.80	6.2	e
2 Abx Micros	56	98.2	0.0	1.8	4.72	6.9	e
3 Microsemi	887	98.6	0.3	1.1	4.90	5.7	e

## Thrombocytes H2




QUALAB tolerance : 25 %

Thrombocytes H2 (G/l)

No. Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1 Z3	219	98.2	0.9	0.9	161.7	7.8	e
2 Abx Micros	56	94.6	1.8	3.6	159.1	8.4	e
3 Microsemi	886	96.5	1.5	2.0	163.1	8.0	e



## Erythrocytes H2




QUALAB tolerance : 25 %

Erythrocytes H2 (T/l)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Z3	219	95.4	2.3	2.3	2.97	5.8	e
2	Abx Micros	56	94.6	1.8	3.6	3.00	6.1	e
3	Microsemi	886	97.9	0.6	1.5	2.97	4.0	e

## CRP H2




QUALAB tolerance : 21 %

CRP H2 (mg/l)

No. Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1 Z3	202	77.7	9.9	12.4	18.5	12.8	e
2 Microsemi	867	94.8	2.0	3.2	22.7	8.7	e
3 Abx Micros	12	91.7	8.3	0.0	23.5	9.3	e*
4 ABX Micros CRP200	44	88.7	6.8	4.5	20.4	11.1	e

## Hemoglobin BG




QUALAB tolerance : 9 %

Hemoglobin BG (g/l)

No. Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1 iStat	11	100.0	0.0	0.0	191.6	1.9	e

# Hematocrit




QUALAB tolerance : 9 %

Hematocrit (l/l)

No. Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1 iStat	17	100.0	0.0	0.0	0.56	2.4	e
2 EPOC	10	90.0	10.0	0.0	0.51	5.4	e*

# Hemoglobin




QUALAB tolerance : 9 %

Hemoglobin (g/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	107	100.0	0.0	0.0	102.2	1.4	e
2	Advia	4	100.0	0.0	0.0	106.0	0.9	e
3	Yumizen/Pentra	13	92.3	0.0	7.7	104.6	1.6	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

## Hematocrit




QUALAB tolerance : 9 %

Hematocrit (l/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	109	97.2	0.0	2.8	0.32	2.5	e
2	Advia	4	100.0	0.0	0.0	0.31	1.8	e
3	Yumizen/Pentra	13	92.3	0.0	7.7	0.30	3.9	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

# Erythrocytes




QUALAB tolerance : 25 %

Erythrocytes (T/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	109	100.0	0.0	0.0	3.55	1.7	e
2	Advia	4	100.0	0.0	0.0	3.63	3.5	e
3	Yumizen/Pentra	13	100.0	0.0	0.0	3.60	6.8	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

# Leucocytes



QUALAB tolerance : 25 %


Leucocytes (G/l)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	108	98.1	1.9	0.0	5.45	7.3	e
2	Advia	4	100.0	0.0	0.0	5.14	13.6	e*
3	Yumizen/Pentra	13	92.3	0.0	7.7	4.58	7.6	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)



## Thrombocytes




QUALAB tolerance : 25 %

Thrombocytes (G/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	107	99.1	0.9	0.0	203.2	7.3	e
2	Advia	4	75.0	25.0	0.0	192.0	18.8	e*
3	Yumizen/Pentra	13	100.0	0.0	0.0	195.7	9.3	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

## Neutrophils




MQ tolerance : 25 %

Neutrophils (G/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	109	97.3	1.8	0.9	3.24	8.0	e
2	Advia	4	75.0	25.0	0.0	3.10	20.4	e*
3	Yumizen/Pentra	12	75.0	16.7	8.3	2.13	20.0	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

# Lymphocytes




MQ tolerance : 25 %

Lymphocytes (G/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	109	98.2	1.8	0.0	1.78	7.9	e
2	Advia	4	100.0	0.0	0.0	1.51	13.9	e*
3	Yumizen/Pentra	12	91.7	0.0	8.3	1.98	4.9	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

## Monocytes




MQ tolerance : 40 %

Monocytes (G/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	109	100.0	0.0	0.0	0.29	25.4	a
2	Advia	4	100.0	0.0	0.0	0.28	27.8	a
3	Yumizen/Pentra	12	75.0	16.7	8.3	0.24	46.5	a

3 additional results were submitted but not published because the method groups were too small. (< results per group)

## Eosinophils




MQ tolerance : 80 %

Eosinophils (G/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	108	100.0	0.0	0.0	0.08	18.7	e
2	Advia	4	75.0	0.0	25.0	0.18	12.5	e
3	Yumizen/Pentra	12	91.7	0.0	8.3	0.06	40.4	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

## Basophiles




MQ tolerance : 80 %  
 (< 0.10: +/- 0.08 G/l)

Basophiles (G/l)

No. Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1 Sysmex	108	93.5	5.6	0.9	0.09	66.4	a
2 Advia	4	75.0	0.0	25.0	0.04	15.7	e
3 Yumizen/Pentra	12	91.7	8.3	0.0	0.05	84.0	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

# MCV




MQ tolerance : 25 %

MCV (fl)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	98	100.0	0.0	0.0	89.7	3.4	e
2	Advia	4	100.0	0.0	0.0	87.2	2.0	e
3	Yumizen/Pentra	8	100.0	0.0	0.0	85.0	2.8	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

# MCH



MQ tolerance : 25 %


MCH (pg)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	98	100.0	0.0	0.0	28.8	1.6	e
2	Advia	4	100.0	0.0	0.0	29.3	3.6	e
3	Yumizen/Pentra	10	100.0	0.0	0.0	29.5	4.1	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)



# MCHC




MQ tolerance : 25 %

MCHC (g/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	99	100.0	0.0	0.0	322	3.3	e
2	Advia	4	100.0	0.0	0.0	339	2.0	e
3	Yumizen/Pentra	10	100.0	0.0	0.0	350	4.2	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

## RDW




MQ tolerance : 25 %

RDW (%)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	96	99.0	0.0	1.0	13.9	2.2	e
2	Yumizen/Pentra	9	100.0	0.0	0.0	13.4	9.6	e*

5 additional results were submitted but not published because the method groups were too small. (< results per group)

# Immature Granulocytes




MQ tolerance : 25 %  
 (< 0.10: +/- 0.10 G/l)

Immature Granulocytes (G/l)

No. Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1 Sysmex	92	98.9	0.0	1.1	0.05	40.7	e*

# Reticulocytes




MQ tolerance : 30 %

Reticulocytes (G/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	59	100.0	0.0	0.0	37.5	13.3	a

6 additional results were submitted but not published because the method groups were too small. (< results per group)

## Hämolyseindex Probe A




MQ tolerance : 30 %

Hämolyseindex Probe A ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	25	100.0	0.0	0.0	121.16	7.8	e
2	Abbott	7	100.0	0.0	0.0	0.81	5.7	e

One result was submitted but not published because the method group was too small. (< 4 results per group)

## Hämolyseindex Probe B




MQ tolerance : 30 %

Hämolyseindex Probe B ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	25	96.0	0.0	4.0	25.75	8.6	e
2	Abbott	7	100.0	0.0	0.0	0.16	7.2	e

One result was submitted but not published because the method group was too small. (< 4 results per group)

## Lipemia index A




MQ tolerance : 30 %

Lipemia index A ( )

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	8	100.0	0.0	0.0	57.00	14.1	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

## Lipemia index B



MQ tolerance : 30 %


Lipemia index B ( )

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	8	75.0	12.5	12.5	15.00	17.5	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)



## Icteria Index A




MQ tolerance : 30 %  
 (< 5.00: +/- 1.50)

Icteria Index A ()

No. Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1 Cobas	8	100.0	0.0	0.0	4.50	11.9	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

## Icteria Index B




MQ tolerance : 30 %  
( < 5.00: +/- 1.50 )

Icteria Index B ( )

No. Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1 Cobas	8	100.0	0.0	0.0	1.00	0.0	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

## Erythrocyte sedimentation rate 1h




MQ tolerance : 40 %

Erythrocyte sedimentation rate 1h (mm/h)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	MINI-CUBE	24	100.0	0.0	0.0	12	27.0	a
2	miniiSed	4	100.0	0.0	0.0	1	0.0	e
3	Sarstedt Sedivette	20	100.0	0.0	0.0	9	29.4	a
4	Sarstedt Microvette	5	100.0	0.0	0.0	10	26.1	a
5	BD Seditainer	46	100.0	0.0	0.0	9	18.3	a
6	Other methods	20	100.0	0.0	0.0	9	24.1	a

## Erythrocyte sedimentation rate 2h



MQ tolerance : 40 %

Erythrocyte sedimentation rate 2h (mm/2h)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sarstedt Sedivette	7	100.0	0.0	0.0	18	27.7	a
2	BD Seditainer	4	100.0	0.0	0.0	20	6.6	a
3	Other methods	4	100.0	0.0	0.0	20	14.1	a

# Hemoglobin HS




MQ tolerance : 9 %

Hemoglobin HS (g/l)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	PixCell HemoScreen	11	90.9	0.0	9.1	168.9	4.0	e*

## Hematocrit HS




MQ tolerance : 9 %

Hematocrit HS (l/l)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	PixCell HemoScreen	11	90.9	0.0	9.1	0.4	4.1	e*

## Erythrocytes HS




MQ tolerance : 25 %

Erythrocytes HS (T/l)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	PixCell HemoScreen	11	90.9	0.0	9.1	4.79	4.3	e

# Leucocytes HS




MQ tolerance : 25 %

Leucocytes HS (G/l)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	PixCell HemoScreen	11	100.0	0.0	0.0	7.69	4.7	e



## Trombocytes HS




MQ tolerance : 25 %

Trombocytes HS (G/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	PixCell HemoScreen	11	100.0	0.0	0.0	253.6	3.9	e


## CRP



No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas b101	393	98.4	0.3	1.3	15.6	6.0	e
2	Cobas	37	94.6	2.7	2.7	17.2	6.4	e
3	Turbidimetry	8	100.0	0.0	0.0	18.0	8.0	e*
4	Afinion	1120	99.3	0.4	0.3	18.1	5.2	e
5	NycoCard SingleTest-	62	71.0	17.7	11.3	17.1	14.7	e
6	Quick Read go	84	94.0	2.4	3.6	17.4	9.4	e
7	Eurolyser	74	78.3	4.1	17.6	22.7	11.5	e
8	Fuji Dri-Chem	14	92.9	0.0	7.1	17.1	8.1	e
9	Autolyser/DiaSys	11	100.0	0.0	0.0	17.5	9.0	e*
10	Piccolo	5	100.0	0.0	0.0	25.5	5.1	e
11	Nephelometry	7	57.1	14.3	28.6	15.0	15.9	e*
12	Celltac chemi	43	100.0	0.0	0.0	17.4	5.5	e

One result was submitted but not published because the method group was too small. (< 4 results per group)

# CRP




QUALAB tolerance : 21 %

CRP (mg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	QuikRead (Vollblut)	21	85.7	9.5	4.8	28.6	11.9	e*

# CRP




QUALAB tolerance : 21 %

CRP (mg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Spinit	12	100.0	0.0	0.0	16.0	5.2	e
2	Abbott	13	100.0	0.0	0.0	18.7	3.6	e
3	AQT 90 FLEX	6	100.0	0.0	0.0	19.0	2.8	e
4	Spotchem D-Concept	4	100.0	0.0	0.0	22.1	2.1	e
5	Other methods	7	100.0	0.0	0.0	18.8	5.1	e


4 additional results were submitted but not published because the method groups were too small. (< results per group)

## IgG




No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Turbidimetry	20	100.0	0.0	0.0	19.46	3.4	e
2	Nephelometry	4	100.0	0.0	0.0	18.90	3.6	e
3	Other methods	5	100.0	0.0	0.0	18.60	4.8	e*

## IgA



No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Turbidimetry	18	100.0	0.0	0.0	3.08	5.5	e
2	Nephelometry	5	100.0	0.0	0.0	3.28	3.9	e
3	Other methods	4	100.0	0.0	0.0	3.02	4.4	e*

## IgM




QUALAB tolerance : 15 %

IgM (g/l)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Turbidimetry	19	100.0	0.0	0.0	1.43	4.8	e
2	Nephelometry	5	100.0	0.0	0.0	1.52	4.7	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

# IgE




QUALAB tolerance : 30 %

IgE (kU/L)

No. Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1 all Participants	6	100.0	0.0	0.0	119	11.3	e*
2 Cobas	6	100.0	0.0	0.0	161	11.3	e*




## Alpha-1-Antitrypsin



No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	9	100.0	0.0	0.0	1.90	9.4	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

## Anti-Streptolysin-Antibodies




MQ tolerance : 25 %

Anti-Streptolysin-Antibodies (kIU/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	13	92.3	7.7	0.0	308	10.0	e
2	Other methods	6	100.0	0.0	0.0	212	1.1	e

## Complement C3




QUALAB tolerance : 15 %

Complement C3 (g/l)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	18	100.0	0.0	0.0	2.33	4.5	e


2 additional results were submitted but not published because the method groups were too small. (< results per group)

## Complement C4



No. Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1 Alinity	5	100.0	0.0	0.0	0.44	4.4	e*
2 Other methods	14	100.0	0.0	0.0	0.43	7.1	e*

# Haptoglobin




MQ tolerance : 25 %

Haptoglobin (g/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	29	100.0	0.0	0.0	1.97	4.6	e

# Transferrin




MQ tolerance : 25 %

Transferrin (g/l)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	34	100.0	0.0	0.0	3.59	2.9	e


## Beta-2 microglobuline



No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	11	100.0	0.0	0.0	3.06	4.0	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

## Rheumatoid factor




MQ tolerance : 25 %

Rheumatoid factor (U/ml)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Atellica	4	100.0	0.0	0.0	29.0	2.8	e
2	Architect	5	100.0	0.0	0.0	43.0	1.4	e
3	Other methods	6	100.0	0.0	0.0	42.3	3.3	e




## Ceruloplasmin



No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Siemens	8	100.0	0.0	0.0	502.00	2.7	e
2	Other methods	4	100.0	0.0	0.0	370.00	1.6	e

## Prealbumin




MQ tolerance : 25 %

Prealbumin (mg/l)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	18	100.0	0.0	0.0	329.39	6.6	e

## Soluble transferrin receptor




MQ tolerance : 25 %

Soluble transferrin receptor (mg/l)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	11	100.0	0.0	0.0	4.1	2.0	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

### free light chain kappa




QUALAB tolerance : 20 %

free light chain kappa (mg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	N Latex	6	100.0	0.0	0.0	10.70	2.6	e
2	Freelite	11	100.0	0.0	0.0	21.33	4.0	e

### free light chain lambda




QUALAB tolerance : 20 %

free light chain lambda (mg/l)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	N Latex	6	100.0	0.0	0.0	9.17	9.2	e*
2	Freelite	11	100.0	0.0	0.0	18.92	5.1	e

### IgE peanut qn




MQ tolerance : 30 %

IgE peanut qn (kU/L)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	14	92.9	0.0	7.1	3.89	9.9	e

### IgE birch qn




QUALAB tolerance : 30 %

IgE birch qn (kU/L)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	15	93.3	0.0	6.7	3.59	8.6	e

## IgE cat qn




QUALAB tolerance : 30 %  
( < 1.50: +/- 0.45 kU/L)

IgE cat qn (kU/L)

No. Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1 all Participants	14	100.0	0.0	0.0	0.36	42.9	e*



### IgE total




QUALAB tolerance : 30 %

IgE total (kU/L)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	13	100.0	0.0	0.0	106	10.3	e

One result was submitted but not published because the method group was too small. (< 4 results per group)

### IgE sx1 qn




MQ tolerance : 30 %

IgE sx1 qn (kU/L)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	10	90.0	10.0	0.0	3.60	18.0	e*

### IgE fx5 qn




MQ tolerance : 30 %

IgE fx5 qn (kU/L)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	10	90.0	0.0	10.0	3.42	9.1	e

## IgE rx1qn




MQ tolerance : 30 %

IgE rx1qn (kU/L)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	8	100.0	0.0	0.0	3.50	10.5	e*

# IgE rx2 qn




MQ tolerance : 30 %  
 (< 1.50: +/- 0.45 kU/L)

IgE rx2 qn (kU/L)

No. Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1 all Participants	8	100.0	0.0	0.0	0.78	16.7	e*

## IgE D. pteronyssinus qn




QUALAB tolerance : 30 %  
 (< 1.50: +/- 0.45 kU/L)

IgE D. pteronyssinus qn (kU/L)

No. Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1 all Participants	12	100.0	0.0	0.0	0.45	18.0	e*

# CRP HS




QUALAB tolerance : 21 %  
 (< 10.00: +/- 2.00 mg/l)

CRP HS (mg/l)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Turbidimetry	10	100.0	0.0	0.0	1.27	9.9	e*

One result was submitted but not published because the method group was too small. (< 4 results per group)

## Lipoprotein (a)




MQ tolerance : 25 %

Lipoprotein (a) (nmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	8	100.0	0.0	0.0	32	6.8	a
2	Others	4	75.0	25.0	0.0	43	16.9	a



# CRP




QUALAB tolerance : 21 %

CRP (mg/l)

No. Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1 AFIAS	139	88.5	5.0	6.5	22.9	9.6	e

## Anti deam. Gliadin IgA




MQ tolerance : 30 %

Anti deam. Gliadin IgA (U/ml)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Other methods	5	80.0	0.0	20.0	7.10	12.1	e*

2 additional results were submitted but not published because the method groups were too small. (< results per group)

## Anti tTG IgA




MQ tolerance : 30 %

Anti tTG IgA (U/ml)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Other methods	6	100.0	0.0	0.0	128.00	1.6	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

# CRP Lumira




QUALAB tolerance : 21 %

CRP Lumira (mg/l)

No. Methode	Total	% OK	% insuff.	% outlier	Target	CV% Type
1 Lumira Dx	16	93.7	0.0	6.3	171.5	11.9 e*

# Albumine




QUALAB tolerance : 12 %  
( < 30.0: +/- 3.6 g/l)

Albumine (g/l)

No. Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1 Cobas	30	100.0	0.0	0.0	30.5	4.2	e
2 Abbott	13	100.0	0.0	0.0	29.1	3.3	e
3 Fuji Dri-Chem	244	99.6	0.4	0.0	34.5	4.2	e
4 Spotchem SP-4430	29	96.6	3.4	0.0	30.0	5.4	e
5 Spotchem D-Concept	232	95.3	4.7	0.0	31.9	5.1	e
6 Piccolo	62	100.0	0.0	0.0	32.7	3.6	e
7 Beckmann	4	100.0	0.0	0.0	30.0	1.8	e
8 Skyla	4	100.0	0.0	0.0	33.5	1.7	e
9 Selectra Pro	11	90.9	9.1	0.0	31.1	5.8	e*
10 Autolyser/DiaSys	8	100.0	0.0	0.0	30.3	4.5	e*

8 additional results were submitted but not published because the method groups were too small. (< results per group)

## Alkaline phosphatase




QUALAB tolerance : 18 %

Alkaline phosphatase (U/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	IFCC	13	100.0	0.0	0.0	113	2.0	e
2	Cobas	31	100.0	0.0	0.0	103	4.7	e
3	Reflotron	6	83.3	0.0	16.7	119	9.1	e*
4	Fuji Dri-Chem	1026	98.5	0.9	0.6	115	6.0	e
5	Spotchem SP-4430	91	96.7	2.2	1.1	91	5.8	e
6	Spotchem D-Concept	533	98.6	0.6	0.8	107	5.4	e
7	Beckman	6	100.0	0.0	0.0	119	3.1	e
8	Dimension	5	100.0	0.0	0.0	99	3.8	e
9	Piccolo	53	100.0	0.0	0.0	116	4.8	e
10	Selectra Pro	15	100.0	0.0	0.0	125	7.5	e
11	Skyla	5	100.0	0.0	0.0	106	2.2	e
12	Autolyser/DiaSys	21	90.5	9.5	0.0	109	9.1	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

# Amylase




QUALAB tolerance : 18 %

Amylase (U/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	10	100.0	0.0	0.0	99	2.7	e
2	Fuji Dri-Chem	746	99.3	0.7	0.0	108	3.8	e
3	Spotchem SP-4430	63	98.4	1.6	0.0	126	6.5	e
4	Spotchem D-Concept	398	98.9	0.8	0.3	103	6.5	e
5	Abbott	7	100.0	0.0	0.0	105	0.8	e
6	Beckman	4	100.0	0.0	0.0	108	1.7	e
7	Piccolo	56	100.0	0.0	0.0	87	3.1	e
8	Selectra Pro	8	100.0	0.0	0.0	124	4.7	e
9	Autolyser/DiaSys	8	87.5	12.5	0.0	92	10.0	e*

8 additional results were submitted but not published because the method groups were too small. (< results per group)

## Pancreatic amylase



QUALAB tolerance : 18 %


Pancreatic amylase (U/l)

No. Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1 IFCC	13	100.0	0.0	0.0	73	2.0	e
2 Cobas	14	100.0	0.0	0.0	73	2.3	e
3 Reflotron	10	100.0	0.0	0.0	83	3.5	e
4 Autolyser/DiaSys	11	100.0	0.0	0.0	70	3.5	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)




## Bilirubin



No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	17	100.0	0.0	0.0	33.9	5.8	e
2	Cobas	30	100.0	0.0	0.0	31.5	3.5	e
3	Reflotron	5	100.0	0.0	0.0	28.6	6.8	e*
4	Fuji Dri-Chem	830	99.5	0.5	0.0	34.8	5.8	e
5	Spotchem SP-4430	82	95.1	3.7	1.2	32.3	8.2	e
6	Spotchem D-Concept	424	97.4	1.9	0.7	25.9	6.1	e
7	Dimension	4	100.0	0.0	0.0	35.6	2.1	e
8	Beckman	6	100.0	0.0	0.0	38.1	4.2	e
9	Piccolo	59	96.6	0.0	3.4	35.4	4.9	e
10	Skyla	4	100.0	0.0	0.0	45.6	3.4	e
11	Selectra Pro	15	93.3	6.7	0.0	29.9	8.5	e*
12	Autolyser/DiaSys	18	100.0	0.0	0.0	35.4	3.6	e

One result was submitted but not published because the method group was too small. (< 4 results per group)

## Bilirubin direct




MQ tolerance : 18 %

Bilirubin direct (µmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Autolyser/DiaSys	7	100.0	0.0	0.0	19.3	7.9	e*
2	Fuji Dri-Chem	21	100.0	0.0	0.0	21.5	4.5	e
3	Piccolo	4	100.0	0.0	0.0	17.0	8.8	e*

# Calcium




QUALAB tolerance : 9 %  
 (< 2.00: +/- 0.18 mmol/l)

Calcium (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	25	100.0	0.0	0.0	2.13	2.7	e
2	Cobas	30	100.0	0.0	0.0	2.17	2.0	e
3	Fuji Dri-Chem	302	95.1	2.6	2.3	2.22	3.8	e
4	Spotchem SP-4430	14	100.0	0.0	0.0	2.26	4.6	e*
5	Spotchem D-Concept	79	92.4	3.8	3.8	1.65	5.0	e
6	Piccolo	54	94.4	0.0	5.6	2.22	1.9	e
7	Selectra Pro	6	100.0	0.0	0.0	2.22	2.3	e
8	Autolyser/DiaSys	9	100.0	0.0	0.0	2.20	3.4	e*

5 additional results were submitted but not published because the method groups were too small. (< results per group)

## Calcium ISE




MQ tolerance : 12 %

Calcium ISE (mmol/l)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	iStat Chem8	5	100.0	0.0	0.0	1.02	0.5	e

One result was submitted but not published because the method group was too small. (< 4 results per group)


# Chloride



No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ISE	26	100.0	0.0	0.0	90	1.8	e
2	Cobas	20	95.0	0.0	5.0	87	0.9	e
3	Fuji Dri-Chem	938	98.2	1.1	0.7	89	2.0	e
4	Spotchem D-Concept	458	98.0	1.1	0.9	92	1.9	e
5	Spotchem EL-SE 1520	78	94.8	2.6	2.6	92	2.6	e
6	Piccolo	28	100.0	0.0	0.0	91	1.4	e
7	iStat Chem8	5	100.0	0.0	0.0	92	0.5	e

6 additional results were submitted but not published because the method groups were too small. (< results per group)

## Cholesterol total




QUALAB tolerance : 10 %

Cholesterol total (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	27	96.3	3.7	0.0	4.09	4.4	e
2	Cobas	27	100.0	0.0	0.0	4.00	2.0	e
3	Reflotron	11	90.9	0.0	9.1	3.89	4.4	e*
4	Fuji Dri-Chem	981	97.1	1.5	1.4	3.81	3.7	e
5	Spotchem SP-4430	87	94.3	2.3	3.4	3.85	3.6	e
6	Spotchem D-Concept	454	96.9	2.0	1.1	4.01	3.9	e
7	Piccolo	31	100.0	0.0	0.0	4.03	2.2	e
8	Cholestech LDX	282	97.5	1.4	1.1	4.06	3.8	e
9	Selectra Pro	14	92.9	7.1	0.0	4.18	4.1	e
10	Autolyser/DiaSys	21	100.0	0.0	0.0	4.04	4.4	e
11	Other methods	4	100.0	0.0	0.0	3.59	1.8	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)


## Cholesterin HDL



No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Wet chemistry, direc	8	100.0	0.0	0.0	1.00	6.5	e
2	Cobas	25	100.0	0.0	0.0	0.68	2.9	e
3	Reflotron	5	100.0	0.0	0.0	0.57	9.5	e*
4	Fuji Dri-Chem	945	99.8	0.0	0.2	0.81	3.7	e
5	Spotchem SP-4430	78	93.6	5.1	1.3	0.58	11.4	e
6	Spotchem D-Concept	437	94.3	4.1	1.6	0.54	10.9	e
7	Dimension	4	100.0	0.0	0.0	0.92	3.9	e
8	Piccolo	30	83.4	3.3	13.3	0.64	8.8	e
9	Pentra/Selectra	13	84.6	7.7	7.7	0.78	11.4	e*
10	Cholestech LDX	282	91.5	5.3	3.2	0.60	10.0	e
11	Architect	14	100.0	0.0	0.0	0.96	3.9	e
12	Autolyser/DiaSys	21	95.2	4.8	0.0	0.84	6.3	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

## Creatine kinase



QUALAB tolerance : 18 %


Creatine kinase (U/l)

No. Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1 IFCC	18	100.0	0.0	0.0	188	2.7	e
2 Cobas	27	100.0	0.0	0.0	181	2.4	e
3 Fuji Dri-Chem	666	97.4	0.9	1.7	203	4.5	e
4 Spotchem SP-4430	45	97.8	2.2	0.0	178	9.2	e
5 Spotchem D-Concept	318	99.4	0.6	0.0	164	6.5	e
6 Piccolo	21	100.0	0.0	0.0	186	5.0	e
7 Selectra Pro	10	100.0	0.0	0.0	193	6.2	e
8 Dimension	4	100.0	0.0	0.0	176	1.4	e
9 Autolyser/DiaSys	18	94.4	5.6	0.0	188	6.2	e
10 Other methods	4	100.0	0.0	0.0	180	2.8	e

One result was submitted but not published because the method group was too small. (&lt; 4 results per group)



## Cholesterol LDL




QUALAB tolerance : 18 %

Cholesterol LDL (mmol/l)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Selectra	5	80.0	20.0	0.0	2.6	10.5	e*
2	Standard chemistry	15	100.0	0.0	0.0	2.8	3.3	e
3	Roche, Cobas	15	100.0	0.0	0.0	2.6	2.6	e
4	Autolyser/DiaSys	11	100.0	0.0	0.0	2.5	6.3	e
5	Beckman	4	100.0	0.0	0.0	2.8	3.5	e

One result was submitted but not published because the method group was too small. (< 4 results per group)

# Iron




QUALAB tolerance : 20 %

Iron (µmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	14	100.0	0.0	0.0	22	3.8	e
2	Cobas	19	100.0	0.0	0.0	22	1.6	e

One result was submitted but not published because the method group was too small. (< 4 results per group)

## Gamma-glutamyltransferase




QUALAB tolerance : 18 %

Gamma-glutamyltransferase (U/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	31	96.8	0.0	3.2	58	5.8	e
2	Reflotron	22	90.9	0.0	9.1	80	6.2	e
3	Fuji Dri-Chem	1134	99.9	0.0	0.1	73	4.9	e
4	Spotchem SP-4430	135	97.8	1.5	0.7	73	6.9	e
5	Spotchem D-Concept	610	98.0	1.0	1.0	70	7.1	e
6	Selectra/Biolis	4	100.0	0.0	0.0	61	2.9	e
7	Abbott	15	100.0	0.0	0.0	62	5.4	e
8	IFCC Beckmann	6	100.0	0.0	0.0	61	2.3	e
9	Piccolo	59	98.3	0.0	1.7	55	3.2	e
10	Skyla	5	100.0	0.0	0.0	60	6.6	e*
11	Selectra Pro	11	100.0	0.0	0.0	61	3.1	e
12	Autolyser/DiaSys	21	100.0	0.0	0.0	62	3.0	e

7 additional results were submitted but not published because the method groups were too small. (< results per group)


## Glucose



No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas Pulse	11	100.0	0.0	0.0	5.5	1.5	e
2	Standard chemistry	26	92.3	7.7	0.0	5.8	4.0	e
3	Cobas	30	100.0	0.0	0.0	5.8	2.1	e
4	Reflotron	19	73.7	10.5	15.8	6.1	6.1	e*
5	Fuji Dri-Chem	1070	98.9	0.4	0.7	5.7	2.5	e
6	Spotchem SP-4430	116	99.1	0.0	0.9	5.8	3.6	e
7	Spotchem D-Concept	571	94.4	4.0	1.6	5.6	4.7	e
8	Dimension	4	75.0	0.0	25.0	6.0	1.7	e
9	Piccolo	71	100.0	0.0	0.0	5.9	1.7	e
10	Cholestech LDX	277	97.8	1.8	0.4	5.5	3.3	e
11	Selectra Pro	16	93.7	0.0	6.3	6.0	3.3	e
12	Autolyser/DiaSys	19	89.5	0.0	10.5	5.9	3.4	e
13	iStat Chem8	7	100.0	0.0	0.0	5.4	1.7	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

# Glucose




QUALAB tolerance : 9 %

Glucose (mmol/l)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Accu-Chek Instant	110	98.2	0.0	1.8	5.7	3.2	e
2	Accu-Chek Aviva	122	94.2	2.5	3.3	6.4	3.8	e
3	Accu-Chek Inform 2	916	99.1	0.5	0.4	6.7	3.1	e
4	Accu-Check Guide	311	99.7	0.0	0.3	5.6	3.1	e
5	Contour XT	1381	95.1	3.6	1.3	6.2	4.1	e
6	Skylla	5	100.0	0.0	0.0	6.0	2.3	e
7	Statstrip/Xpress	92	100.0	0.0	0.0	5.8	3.5	e
8	Glucocard	10	90.0	10.0	0.0	7.2	6.5	e*
9	Hemocue 201+ P-equiv	114	97.3	1.8	0.9	7.2	3.2	e
10	Hemocue 201RT P-equiv	127	99.2	0.0	0.8	7.2	2.8	e
11	CardioChek	4	75.0	25.0	0.0	7.3	6.8	e*
12	Freestyle Freedom li	4	100.0	0.0	0.0	6.1	2.1	e
13	Contour NEXT	38	89.5	7.9	2.6	5.9	5.2	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

## Glucose B




QUALAB tolerance : 9 %

Glucose B (mmol/l)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Hemocue 201+ (alt)	32	90.6	6.3	3.1	7.0	4.5	e
2	OneTouch Verio	26	100.0	0.0	0.0	5.6	2.5	e
3	Contour 2 (5s)	8	87.5	12.5	0.0	4.9	4.3	e*
4	Healthpro	23	82.7	4.3	13.0	9.8	4.2	e
5	Mylife UNIO	424	96.7	2.1	1.2	6.7	4.1	e
6	mylife Pura	95	87.4	6.3	6.3	6.3	4.4	e
7	Alpha Check	16	87.5	12.5	0.0	9.1	5.4	e*

One result was submitted but not published because the method group was too small. (< 4 results per group)


## Uric Acid



No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	28	100.0	0.0	0.0	289	2.7	e
2	Cobas	27	100.0	0.0	0.0	285	3.2	e
3	Reflotron	10	100.0	0.0	0.0	307	5.1	e*
4	Fuji Dri-Chem	1054	99.0	0.5	0.5	324	2.7	e
5	Spotchem SP-4430	114	98.2	1.8	0.0	271	5.1	e
6	Spotchem D-Concept	570	98.4	0.4	1.2	292	3.8	e
7	Piccolo	37	89.2	8.1	2.7	235	7.2	e
8	Skyla	5	100.0	0.0	0.0	268	5.6	e*
9	Selectra Pro	16	100.0	0.0	0.0	286	2.0	e
10	Autolyser/DiaSys	19	100.0	0.0	0.0	279	4.7	e

One result was submitted but not published because the method group was too small. (< 4 results per group)

## Urea



QUALAB tolerance : 15 %


Urea (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	14	100.0	0.0	0.0	10.9	5.8	e
2	Standard chemistry	9	100.0	0.0	0.0	10.9	3.0	e
3	Cobas	28	100.0	0.0	0.0	10.3	3.2	e
4	Reflotron	5	100.0	0.0	0.0	10.2	4.3	e*
5	Fuji Dri-Chem	635	99.6	0.2	0.2	10.6	2.1	e
6	Spotchem SP-4430	62	93.5	6.5	0.0	10.2	7.5	e
7	Spotchem D-Concept	328	94.5	3.4	2.1	10.5	7.0	e
8	Piccolo	64	100.0	0.0	0.0	9.8	1.8	e
9	Skyla	5	100.0	0.0	0.0	10.6	4.3	e*
10	Selectra Pro	10	100.0	0.0	0.0	10.4	5.3	e
11	Autolyser/DiaSys	15	100.0	0.0	0.0	10.6	5.0	e
12	Other methods	7	100.0	0.0	0.0	10.2	3.3	e
13	iStat Chem8	5	100.0	0.0	0.0	13.6	5.0	e*

One result was submitted but not published because the method group was too small. (< 4 results per group)



# Potassium




QUALAB tolerance : 6 %  
( < 3.30: +/- 0.20 mmol/l)

Potassium (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ISE	38	100.0	0.0	0.0	3.51	2.2	e
2	Cobas	30	100.0	0.0	0.0	3.59	1.0	e
3	Reflotron	19	73.7	15.8	10.5	3.58	4.9	e*
4	Fuji Dri-Chem	1107	98.7	0.4	0.9	3.40	1.9	e
5	Spotchem D-Concept	579	97.8	0.3	1.9	3.50	2.1	e
6	Autolyser/DiaSys	9	66.7	22.2	11.1	3.26	4.5	e*
7	Spotchem EL-SE 1520	102	100.0	0.0	0.0	3.50	2.4	e
8	Piccolo	41	78.0	9.8	12.2	3.78	4.4	e
9	iStat Chem8	8	87.5	0.0	12.5	3.50	0.0	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

# Creatinine




QUALAB tolerance : 18 %

Creatinine (µmol/l)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	11	100.0	0.0	0.0	148	3.2	e
2	Standard chemistry	7	85.7	0.0	14.3	152	2.6	e
3	Cobas	31	100.0	0.0	0.0	146	3.9	e
4	Reflotron	39	94.9	5.1	0.0	161	8.9	e
5	Fuji Dri-Chem	1164	99.2	0.1	0.7	136	4.4	e
6	Spotchem SP-4430	153	99.3	0.0	0.7	146	2.6	e
7	Spotchem D-Concept	615	99.3	0.2	0.5	146	3.0	e
8	Enzymatic	7	100.0	0.0	0.0	152	7.3	e*
9	Piccolo	69	95.7	1.4	2.9	151	6.6	e
10	Selectra Pro	16	100.0	0.0	0.0	152	4.0	e
11	Skyla	5	100.0	0.0	0.0	141	4.2	e
12	Autolyser/DiaSys	21	95.2	4.8	0.0	147	7.3	e
13	Other methods	4	100.0	0.0	0.0	149	5.0	e*
14	EPOC	10	70.0	10.0	20.0	156	8.8	e*

One result was submitted but not published because the method group was too small. (< 4 results per group)

## Creatinine E




QUALAB tolerance : 18 %

Creatinine E (µmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	iStat Chem8	33	100.0	0.0	0.0	163	3.3	e
2	ABL700/800	13	100.0	0.0	0.0	156	6.5	e

## eGFR CKD-EPI




MQ tolerance : 30 %

eGFR CKD-EPI ( )

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	56	100.0	0.0	0.0	34	7.1	e
2	Reflotron	11	90.9	9.1	0.0	32	16.0	e*
3	Fuji Dri-Chem	416	93.5	2.4	4.1	39	8.9	e
4	Spotchem	278	90.6	3.6	5.8	36	9.1	e

## eGFR Cockcroft-Gault




MQ tolerance : 30 %

eGFR Cockcroft-Gault ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Fuji Dri-Chem	38	86.8	5.3	7.9	43	17.1	e
2	Spotchem	15	100.0	0.0	0.0	43	18.0	e*

4 additional results were submitted but not published because the method groups were too small. (< results per group)

## eGFR MDRD




MQ tolerance : 30 %

eGFR MDRD ()

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Fuji Dri-Chem	4	75.0	0.0	25.0	46	12.3	e*

4 additional results were submitted but not published because the method groups were too small. (< results per group)

# LDH




QUALAB tolerance : 18 %

LDH (U/l)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	IFCC	38	100.0	0.0	0.0	153	5.1	e
2	Cobas	14	100.0	0.0	0.0	158	3.4	e
3	Fuji Dri-Chem	121	98.3	0.0	1.7	128	5.3	e
4	Spotchem SP-4430	12	91.7	8.3	0.0	116	11.0	e*
5	Spotchem D-Concept	42	95.2	0.0	4.8	132	9.7	e
6	Autolyser/DiaSys	7	100.0	0.0	0.0	161	3.2	e

7 additional results were submitted but not published because the method groups were too small. (< results per group)

## Magnesium



QUALAB tolerance : 12 %  
( < 0.70: +/- 0.09 mmol/l)


Magnesium (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	21	100.0	0.0	0.0	0.75	4.0	e
2	Cobas	20	100.0	0.0	0.0	0.78	3.5	e
3	Fuji Dri-Chem	79	98.7	1.3	0.0	0.75	4.2	e
4	Spotchem D-Concept	36	100.0	0.0	0.0	0.69	3.8	e
5	Spotchem SP-4430	4	100.0	0.0	0.0	0.67	5.8	e*
6	Beckman	5	100.0	0.0	0.0	0.79	3.6	e*
7	Piccolo	4	100.0	0.0	0.0	0.82	5.1	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)



## Sodium




QUALAB tolerance : 6 %

Sodium (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ISE	38	100.0	0.0	0.0	130	1.4	e
2	Cobas	30	100.0	0.0	0.0	129	0.9	e
3	Fuji Dri-Chem	1015	98.3	1.1	0.6	131	1.3	e
4	Spotchem D-Concept	504	99.6	0.0	0.4	128	1.5	e
5	Spotchem EL-SE 1520	86	100.0	0.0	0.0	126	1.9	e
6	Piccolo	40	100.0	0.0	0.0	126	2.2	e
7	iStat Chem8	7	100.0	0.0	0.0	129	0.4	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

## Phosphate




QUALAB tolerance : 15 %

Phosphate (mmol/l)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	22	100.0	0.0	0.0	1.0	4.1	e
2	Cobas	25	96.0	4.0	0.0	1.0	4.2	e
3	Fuji Dri-Chem	74	97.2	1.4	1.4	1.1	4.6	e
4	Spotchem D-Concept	14	92.9	0.0	7.1	1.1	3.8	e
5	Piccolo	7	71.4	0.0	28.6	1.4	3.1	e

12 additional results were submitted but not published because the method groups were too small. (< results per group)

## Protein total




QUALAB tolerance : 12 %

Protein total (g/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	24	95.8	4.2	0.0	47.9	5.0	e
2	Cobas	26	100.0	0.0	0.0	46.7	2.7	e
3	Fuji Dri-Chem	193	99.0	0.5	0.5	44.4	3.2	e
4	Spotchem SP-4430	26	92.4	3.8	3.8	46.2	6.5	e
5	Spotchem D-Concept	186	95.1	2.7	2.2	42.0	5.3	e
6	Piccolo	50	98.0	0.0	2.0	49.3	1.7	e
7	Skyla	4	100.0	0.0	0.0	48.5	2.7	e
8	Selectra Pro	7	100.0	0.0	0.0	48.0	3.2	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

## Aspartate aminotransferase




QUALAB tolerance : 18 %

Aspartate aminotransferase (U/l)

No. Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1 IFCC with PP	27	100.0	0.0	0.0	82	4.4	e
2 Cobas	28	100.0	0.0	0.0	82	2.7	e
3 Reflotron	27	92.6	0.0	7.4	95	8.7	e
4 Fuji Dri-Chem	1144	98.8	0.9	0.3	82	3.9	e
5 Spotchem SP-4430	145	99.3	0.0	0.7	63	5.2	e
6 Spotchem D-Concept	609	98.9	0.3	0.8	65	4.2	e
7 Piccolo	75	98.7	0.0	1.3	80	3.0	e
8 Skyla	5	100.0	0.0	0.0	84	4.6	e
9 Selectra Pro	16	100.0	0.0	0.0	84	4.2	e
10 Autolyser/DiaSys	21	100.0	0.0	0.0	86	5.0	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

## Alanine aminotransferase




QUALAB tolerance : 18 %

Alanine aminotransferase (U/l)

No. Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1 IFCC with PP	22	100.0	0.0	0.0	57	6.2	e
2 Cobas	31	100.0	0.0	0.0	57	3.3	e
3 Reflotron	20	85.0	10.0	5.0	51	10.2	e*
4 Fuji Dri-Chem	1156	98.3	0.7	1.0	62	5.1	e
5 Spotchem SP-4430	148	97.9	1.4	0.7	41	6.6	e
6 Spotchem D-Concept	619	94.6	3.6	1.8	38	10.2	e
7 Piccolo	73	98.6	0.0	1.4	53	6.5	e
8 Skyla	5	100.0	0.0	0.0	49	6.4	e*
9 Selectra Pro	16	93.7	0.0	6.3	58	3.8	e
10 Autolyser/DiaSys	21	100.0	0.0	0.0	60	4.9	e
11 Other methods	5	100.0	0.0	0.0	56	6.0	e*

One result was submitted but not published because the method group was too small. (< 4 results per group)

## Triglycerides




QUALAB tolerance : 18 %

Triglycerides (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	13	100.0	0.0	0.0	1.34	2.6	e
2	Standard chemistry	12	100.0	0.0	0.0	1.41	4.8	e
3	Cobas	27	100.0	0.0	0.0	1.44	2.7	e
4	Reflotron	7	57.1	0.0	42.9	1.57	7.2	e*
5	Fuji Dri-Chem	967	99.3	0.5	0.2	1.37	4.9	e
6	Spotchem SP-4430	83	100.0	0.0	0.0	1.33	4.5	e
7	Spotchem D-Concept	442	96.6	0.0	3.4	1.42	4.5	e
8	Piccolo	29	100.0	0.0	0.0	1.57	2.4	e
9	Cholestech LDX	281	99.6	0.0	0.4	1.30	3.4	e
10	Selectra Pro	13	100.0	0.0	0.0	1.44	5.2	e
11	Autolyser/DiaSys	21	90.4	4.8	4.8	1.33	6.6	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

# Lithium




QUALAB tolerance : 15 %  
 (< 1.00: +/- 0.15 mmol/l)

Lithium (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas Integra 800/40	4	100.0	0.0	0.0	0.90	3.6	e
2	Other methods	19	100.0	0.0	0.0	0.90	4.6	e

# Lactate



QUALAB tolerance : 18 %


Lactate (mmol/l)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	20	100.0	0.0	0.0	2.71	3.3	e

One result was submitted but not published because the method group was too small. (< 4 results per group)



## HbA1c sample A




QUALAB tolerance : 9 %

HbA1c sample A (%)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	6	100.0	0.0	0.0	6.3	1.3	e
2	Roche, Cobas	17	100.0	0.0	0.0	6.4	2.8	e
3	HPLC	9	100.0	0.0	0.0	6.4	2.4	e
4	Afinion	534	97.7	0.4	1.9	6.2	2.5	e
5	Cobas b101	197	95.5	2.0	2.5	6.0	3.5	e
6	DCA2000/Vantage	127	94.5	3.1	2.4	6.4	3.8	e
7	Celltac chemi	20	90.0	5.0	5.0	5.9	4.2	e
8	NycoCard	9	66.7	11.1	22.2	6.4	5.1	c
9	Eurolyser	8	100.0	0.0	0.0	6.3	2.5	e
10	A1c Now	233	94.4	4.7	0.9	6.0	4.5	e
11	AFIAS	102	90.2	7.8	2.0	6.1	5.2	e
12	Others	25	84.0	4.0	12.0	6.4	4.9	e
13	Spinit	18	94.4	5.6	0.0	6.4	5.4	e*
14	Quick Read go	4	100.0	0.0	0.0	6.8	4.3	e*

One result was submitted but not published because the method group was too small. (< 4 results per group)

## HbA1c sample B




QUALAB tolerance : 9 %  
( < 5.0: +/- 0.5 %)

HbA1c sample B (%)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	5	100.0	0.0	0.0	4.6	1.2	e
2	Roche, Cobas	18	100.0	0.0	0.0	4.8	4.8	e*
3	HPLC	9	100.0	0.0	0.0	4.6	3.5	e*
4	Afinion	775	97.7	1.4	0.9	4.8	3.2	e
5	Cobas b101	196	97.5	2.0	0.5	4.5	3.4	e
6	DCA2000/Vantage	188	92.5	6.4	1.1	5.0	4.8	e
7	Celltac chemi	14	100.0	0.0	0.0	4.2	4.1	e*
8	NycoCard	4	25.0	25.0	50.0	4.7	10.9	c
9	Eurolyser	5	100.0	0.0	0.0	4.6	3.5	e*
10	A1c Now	6	100.0	0.0	0.0	4.7	2.9	e*
11	AFIAS	120	95.9	3.3	0.8	4.9	4.1	e
12	Spinit	9	88.9	11.1	0.0	5.1	5.4	e*
13	Others	15	93.3	6.7	0.0	4.5	5.9	e*
14	Quick Read go	5	80.0	0.0	20.0	4.9	2.6	e*

One result was submitted but not published because the method group was too small. (< 4 results per group)


## pCO2



No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL700/800	107	100.0	0.0	0.0	2.88	3.2	e
2	ABL80 FLEX CO-OX / O	5	80.0	0.0	20.0	3.07	5.3	e*
3	ABL90 FLEX / PLUS	114	98.2	0.0	1.8	3.02	2.3	e
4	Cobas b 123	15	93.3	6.7	0.0	3.00	4.3	e
5	Cobas b 221	7	100.0	0.0	0.0	3.03	3.3	e
6	GEM	8	100.0	0.0	0.0	2.80	1.6	e
7	iStat	43	97.7	2.3	0.0	2.62	3.9	e
8	EPOC	50	94.0	4.0	2.0	2.62	5.4	e
9	IL	4	100.0	0.0	0.0	2.85	2.0	e

9 additional results were submitted but not published because the method groups were too small. (< results per group)

**pO2**




QUALAB tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL700/800	106	94.4	2.8	2.8	9.88	4.9	e
2	ABL80 FLEX CO-OX / O	5	80.0	0.0	20.0	8.53	6.7	e*
3	ABL90 FLEX / PLUS	115	88.7	3.5	7.8	7.69	5.8	e
4	Cobas b 123	17	88.2	0.0	11.8	8.90	5.6	e
5	Cobas b 221	4	100.0	0.0	0.0	12.13	6.5	e*
6	GEM	8	100.0	0.0	0.0	9.15	6.8	e*
7	iStat	40	90.0	5.0	5.0	11.61	8.5	e
8	EPOC	50	84.0	4.0	12.0	9.84	8.0	e
9	IL	4	100.0	0.0	0.0	9.35	3.6	e

8 additional results were submitted but not published because the method groups were too small. (< results per group)

# K04 Blood gases

## pH




QUALAB tolerance : 1 %

pH ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL700/800	106	100.0	0.0	0.0	7.57	0.1	e
2	ABL80 FLEX CO-OX / O	5	100.0	0.0	0.0	7.58	0.2	e
3	ABL90 FLEX / PLUS	115	99.1	0.0	0.9	7.59	0.1	e
4	Cobas b 123	16	100.0	0.0	0.0	7.57	0.1	e
5	Cobas b 221	7	100.0	0.0	0.0	7.57	0.3	e*
6	GEM	8	100.0	0.0	0.0	7.63	0.1	e
7	iStat	44	95.5	0.0	4.5	7.65	0.1	e
8	EPOC	49	100.0	0.0	0.0	7.63	0.2	e
9	IL	5	100.0	0.0	0.0	7.64	0.1	e

8 additional results were submitted but not published because the method groups were too small. (< results per group)

## Glucose BG




QUALAB tolerance : 9 %

Glucose BG (mmol/l)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	GEM	4	100.0	0.0	0.0	14.7	2.0	e
2	Cobas b 123	10	80.0	20.0	0.0	14.3	5.9	e*
3	iStat	10	90.0	0.0	10.0	13.2	2.7	e
4	EPOC	39	97.4	0.0	2.6	14.0	4.2	e
5	ABL700/800	97	100.0	0.0	0.0	14.1	2.2	e
6	ABL90 FLEX / PLUS	100	99.0	1.0	0.0	13.6	2.5	e

8 additional results were submitted but not published because the method groups were too small. (< results per group)

## Hemoglobin BG




QUALAB tolerance : 9 %

Hemoglobin BG (g/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL700/800	98	99.0	0.0	1.0	191.7	1.9	e
2	ABL90 FLEX / PLUS	102	99.0	0.0	1.0	192.2	0.4	e
3	ABL80 FLEX CO-OX / O	6	100.0	0.0	0.0	189.5	1.2	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

## Potassium BG



QUALAB tolerance : 6 %


Potassium BG (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	GEM	5	100.0	0.0	0.0	5.5	1.3	e
2	Cobas b 123	19	94.7	0.0	5.3	5.4	0.8	e
3	iStat	16	93.7	0.0	6.3	5.3	0.7	e
4	EPOC	42	97.6	0.0	2.4	4.6	2.7	e
5	ABL700/800	98	100.0	0.0	0.0	5.4	1.1	e
6	ABL90 FLEX / PLUS	109	99.1	0.0	0.9	5.4	0.8	e

9 additional results were submitted but not published because the method groups were too small. (< results per group)



## Sodium BG




QUALAB tolerance : 6 %

Sodium BG (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	GEM	6	100.0	0.0	0.0	122.0	0.0	e
2	Cobas b 123	19	100.0	0.0	0.0	122.3	0.9	e
3	iStat	16	93.7	0.0	6.3	124.3	0.6	e
4	EPOC	39	100.0	0.0	0.0	120.3	0.6	e
5	ABL700/800	97	100.0	0.0	0.0	126.1	0.9	e
6	ABL90 FLEX / PLUS	108	100.0	0.0	0.0	125.6	0.5	e

7 additional results were submitted but not published because the method groups were too small. (< results per group)

## Chlorid-BG




QUALAB tolerance : 6 %

Chlorid-BG (mmol/l)

No. Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1 Cobas b 123	8	100.0	0.0	0.0	70.1	0.4	e
2 EPOC	11	100.0	0.0	0.0	74.1	2.0	e
3 ABL700/800	92	95.6	1.1	3.3	67.3	2.6	e
4 ABL90 FLEX / PLUS	103	99.0	0.0	1.0	63.6	1.5	e

6 additional results were submitted but not published because the method groups were too small. (< results per group)

## Calcium-BG




MQ tolerance : 12 %  
( < 2.00: +/- 0.24 mmol/l)

Calcium-BG (mmol/l)

No. Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1 GEM	5	100.0	0.0	0.0	0.27	2.6	e
2 Cobas b123	12	100.0	0.0	0.0	0.16	30.0	e*
3 Roche, Cobas	7	100.0	0.0	0.0	0.27	29.2	e*
4 iStat	13	92.3	0.0	7.7	0.31	0.9	e
5 EPOC	37	100.0	0.0	0.0	0.27	6.1	e
6 ABL700/800	97	100.0	0.0	0.0	0.37	4.0	e
7 ABL90 FLEX / PLUS	106	98.1	0.0	1.9	0.37	2.3	e

6 additional results were submitted but not published because the method groups were too small. (< results per group)


## FHHb



No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL90 FLEX / PLUS	7	100.0	0.0	0.0	20.900	0.3	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

## Lactate-BG




QUALAB tolerance : 18 %

Lactate-BG (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	GEM	5	100.0	0.0	0.0	11.90	1.5	e
2	Cobas b123	9	100.0	0.0	0.0	10.80	4.8	e
3	Roche, Cobas	6	100.0	0.0	0.0	11.58	11.3	e*
4	IL	4	100.0	0.0	0.0	11.85	2.8	e
5	EPOC	36	86.1	8.3	5.6	7.39	12.0	e
6	iStat	14	100.0	0.0	0.0	10.97	1.9	e
7	ABL700/800	99	100.0	0.0	0.0	10.31	4.7	e
8	ABL90 FLEX / PLUS	108	100.0	0.0	0.0	10.49	2.8	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)


## sO2 OR



No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	iStat	16	100.0	0.0	0.0	98.375	0.5	e
2	ABL700/800	87	100.0	0.0	0.0	70.093	0.1	e
3	ABL90 FLEX / PLUS	93	100.0	0.0	0.0	70.094	0.1	e
4	ABL80 FLEX CO-OX / O	4	100.0	0.0	0.0	70.250	0.1	e

One result was submitted but not published because the method group was too small. (< 4 results per group)

## FO2Hb OR




MQ tolerance : 20 %

FO2Hb OR (%)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL700/800	86	98.8	0.0	1.2	48.877	0.3	e
2	ABL90 FLEX / PLUS	93	100.0	0.0	0.0	48.953	0.2	e
3	ABL80 FLEX CO-OX / O	4	100.0	0.0	0.0	48.850	0.2	e

## FCOHb OR




MQ tolerance : 20 %

FCOHb OR (%)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL700/800	88	97.7	0.0	2.3	20.274	1.1	e
2	ABL90 FLEX / PLUS	93	100.0	0.0	0.0	20.166	0.7	e
3	ABL80 FLEX CO-OX / O	4	100.0	0.0	0.0	20.450	0.9	e



## FMetHb OR




MQ tolerance : 20 %

FMetHb OR (%)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL700/800	88	98.9	0.0	1.1	10.009	1.1	e
2	ABL90 FLEX / PLUS	93	100.0	0.0	0.0	9.994	0.7	e
3	ABL80 FLEX CO-OX / O	4	100.0	0.0	0.0	10.000	0.0	e

## FHbF OR




MQ tolerance : 20 %

FHbF OR (%)

No. Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1 ABL700/800	4	100.0	0.0	0.0	54.500	7.0	e*
2 ABL90 FLEX / PLUS	38	100.0	0.0	0.0	52.368	3.6	e

## Bilirubin OR




QUALAB tolerance : 18 %

Bilirubin OR (µmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL700/800	5	60.0	0.0	40.0	432.0	2.0	e
2	ABL90 FLEX / PLUS	34	100.0	0.0	0.0	443.6	0.5	e

# Troponin I




QUALAB tolerance : 24 %

Troponin I (ng/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Pathfast	14	100.0	0.0	0.0	13808.6	7.8	e
2	Vidas	11	100.0	0.0	0.0	15086.5	5.9	e
3	Architect High Sensi	10	100.0	0.0	0.0	3466.6	6.8	e

9 additional results were submitted but not published because the method groups were too small. (< results per group)

## Troponin T




QUALAB tolerance : 24 %

Troponin T (ng/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas hs	10	100.0	0.0	0.0	3324.00	4.2	e
2	Cobas hs STAT	12	100.0	0.0	0.0	3349.08	3.9	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

# Myoglobin




QUALAB tolerance : 30 %

Myoglobin (µg/l)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas E / Elecsys	8	100.0	0.0	0.0	165.5	3.9	e
2	Abbott	5	100.0	0.0	0.0	182.0	3.6	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

### CK-MB mass




MQ tolerance : 40 %

CK-MB mass (µg/l)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas E / Elecsys	9	100.0	0.0	0.0	28.9	3.6	e

9 additional results were submitted but not published because the method groups were too small. (< results per group)


# BNP



No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Other methods	5	80.0	20.0	0.0	1289.0	19.4	e*
2 additional results were submitted but not published because the method groups were too small. (< results per group)								



## NT-proBNP




QUALAB tolerance : 27 %

NT-proBNP (ng/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Pathfast	10	100.0	0.0	0.0	5244.7	11.5	e*
2	AQT 90 FLEX	4	100.0	0.0	0.0	3100.0	7.0	a
3	VIDAS	10	100.0	0.0	0.0	1560.0	14.7	a
4	Cobas E / Elecsys	20	100.0	0.0	0.0	1859.3	5.4	e
5	Abbott	8	87.5	12.5	0.0	2187.0	12.3	e*

5 additional results were submitted but not published because the method groups were too small. (< results per group)

# TSH




QUALAB tolerance : 18 %

TSH (mU/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas E / Elecsys	25	100.0	0.0	0.0	35.81	4.1	e
2	Abbott	12	100.0	0.0	0.0	28.27	3.8	e
3	VIDAS	14	92.9	7.1	0.0	40.55	7.2	e
4	Dimension	5	100.0	0.0	0.0	36.50	6.0	e*
5	AFIAS	19	84.2	0.0	15.8	62.96	6.2	e
6	Other methods	4	100.0	0.0	0.0	38.03	4.7	e*

4 additional results were submitted but not published because the method groups were too small. (< results per group)

# T3




MQ tolerance : 20 %

T3 (nmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	AFIAS	5	100.0	0.0	0.0	2.6	3.6	e
2	Abbott	4	100.0	0.0	0.0	4.7	3.0	e

One result was submitted but not published because the method group was too small. (< 4 results per group)

# T4




MQ tolerance : 20 %

T4 (nmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	AFIAS	5	80.0	0.0	20.0	248	10.5	e*
2	Abbott	4	100.0	0.0	0.0	209	3.6	e

One result was submitted but not published because the method group was too small. (< 4 results per group)

# FT3




QUALAB tolerance : 18 %

FT3 (pmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas E / Elecsys	21	100.0	0.0	0.0	22.1	2.4	e
2	ADVIA Centaur XP/CP	4	100.0	0.0	0.0	21.9	7.9	e*
3	Abbott	10	90.0	10.0	0.0	19.3	8.5	e*
4	VIDAS	7	85.7	14.3	0.0	19.7	9.8	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)


# FT4



No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas E / Elecsys	22	95.5	0.0	4.5	67.7	4.7	e
2	Abbott	11	90.9	0.0	9.1	44.4	8.5	e*
3	VIDAS	8	100.0	0.0	0.0	69.6	6.3	e
4	Other methods	8	100.0	0.0	0.0	73.4	6.7	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

# Testosterone




QUALAB tolerance : 30 %

Testosterone (nmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	11	100.0	0.0	0.0	27.9	4.2	e
2	ADVIA Centaur XP/CP	5	100.0	0.0	0.0	25.7	7.3	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

## Estradiol




QUALAB tolerance : 30 %

Estradiol (pmol/l)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	9	100.0	0.0	0.0	2647	3.8	e
2	ADVIA Centaur XP/CP	5	100.0	0.0	0.0	4354	12.3	e*
3	all Participants	4	100.0	0.0	0.0	2498	10.7	e*
4	Abbott	6	100.0	0.0	0.0	2263	6.3	e



# SHBG




MQ tolerance : 30 %

SHBG (nmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	15	100.0	0.0	0.0	34.5	4.3	e
2	Abbott	5	100.0	0.0	0.0	37.9	8.8	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

# Cortisol




QUALAB tolerance : 20 %

Cortisol (nmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas E / Elecsys	18	100.0	0.0	0.0	877	3.4	e
2	Abbott	5	100.0	0.0	0.0	794	6.1	e*

4 additional results were submitted but not published because the method groups were too small. (< results per group)

# Progesteron




MQ tolerance : 30 %

Progesteron (nmol/l)

No. Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1 Cobas	6	100.0	0.0	0.0	82.8	4.1	e
2 Abbott	5	100.0	0.0	0.0	64.3	9.2	e*
3 Other methods	4	100.0	0.0	0.0	87.8	13.8	e*

One result was submitted but not published because the method group was too small. (< 4 results per group)

# DHEAS




MQ tolerance : 30 %

DHEAS (µmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	11	100.0	0.0	0.0	17.70	8.2	e
2	Abbott	4	100.0	0.0	0.0	15.92	3.2	e

One result was submitted but not published because the method group was too small. (< 4 results per group)

## Luteinizing hormone




QUALAB tolerance : 24 %

Luteinizing hormone (U/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	9	100.0	0.0	0.0	72.0	6.2	e
2	ADVIA Centaur XP/CP	5	100.0	0.0	0.0	59.9	4.8	e
3	Abbott	6	100.0	0.0	0.0	50.6	3.2	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

## Follicle-stimulating hormone




QUALAB tolerance : 24 %

Follicle-stimulating hormone (U/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	10	100.0	0.0	0.0	39.7	2.6	e
2	ADVIA Centaur XP/CP	5	100.0	0.0	0.0	39.1	6.2	e
3	Architect	7	100.0	0.0	0.0	39.0	4.0	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

# Prolactine




QUALAB tolerance : 24 %

Prolactine (µg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ADVIA Centaur XP/CP	4	100.0	0.0	0.0	37.2	14.7	e*
2	Cobas/Roche	11	90.9	0.0	9.1	58.6	5.0	e
3	Abbott	5	100.0	0.0	0.0	47.9	8.4	e*

# Insulin



MQ tolerance : 25 %


Insulin (pmol/l)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	15	93.3	0.0	6.7	1126	6.7	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)



# HGH




MQ tolerance : 25 %

HGH (µg/l)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	7	100.0	0.0	0.0	21.80	3.2	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

## Freies Testosteron




MQ tolerance : 25 %

Freies Testosteron (pmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	IDS	4	100.0	0.0	0.0	79.6	5.9	e


4 additional results were submitted but not published because the method groups were too small. (< results per group)

# IGF-1



No. Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1 Liaison	6	100.0	0.0	0.0	110	13.2	a
2 Other methods	6	100.0	0.0	0.0	72	13.3	e*

## Troponin T CR




QUALAB tolerance : 24 %

Troponin T CR (ng/l)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas h 232	1268	93.0	5.0	2.0	286.00	12.1	e

## D-dimer CR




QUALAB tolerance : 21 %

D-dimer CR (mg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas h 232	1262	84.9	10.4	4.7	0.56	12.5	e
2	Lumira Dx	10	60.0	0.0	40.0	0.53	2.1	a

## CKMB- K8




MQ tolerance : 40 %

CKMB- K8 (µg/l)


No. Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1 Cobas h 232	9	100.0	0.0	0.0	25.5	11.4	e

## NT-proBNP CR



No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Lumira Dx	5	100.0	0.0	0.0	1038	9.2	e*
2	Cobas h 232	791	91.3	5.7	3.0	312	14.7	e

## PCO2 CCA




QUALAB tolerance : 12 %

PCO2 CCA (kPa)

No. Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1 OPTI CCA	12	91.7	8.3	0.0	5.65	6.8	e*



## PO2 CCA




QUALAB tolerance : 15 %

PO2 CCA (kPa)


No. Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1 OPTI CCA	12	83.4	8.3	8.3	12.58	6.7	e*

# pH CCA



No. Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1 OPTI CCA	11	90.9	9.1	0.0	7.41	0.4	e*

## Potassium CCA




QUALAB tolerance : 6 %

Potassium CCA (mmol/l)

No. Methode	Total	% OK	% insuff.	% outlier	Target	CV% Type
1 OPTI CCA	6	100.0	0.0	0.0	4.8	1.7 e

## Sodium CCA




QUALAB tolerance : 6 %

Sodium CCA (mmol/l)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	OPTI CCA	5	100.0	0.0	0.0	149.0	0.6	e


## Ferritin



No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Dimension	5	100.0	0.0	0.0	103.00	3.1	e
2	Beckman	6	83.3	16.7	0.0	81.75	12.3	e*
3	Cobas E / Elecsys	23	100.0	0.0	0.0	102.49	5.2	e
4	Abbott	13	100.0	0.0	0.0	131.08	3.5	e
5	Mini Vidas	7	100.0	0.0	0.0	79.04	11.0	e*
6	AFIAS	29	93.1	0.0	6.9	83.73	8.5	e
7	Eurolyser	4	100.0	0.0	0.0	65.80	10.5	e*

8 additional results were submitted but not published because the method groups were too small. (< results per group)

## Vitamin B12




QUALAB tolerance : 21 %

Vitamin B12 (pmol/l)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	5	100.0	0.0	0.0	291.00	5.9	e*
2	Cobas E / Elecsys	19	100.0	0.0	0.0	319.28	4.7	e
3	Abbott	11	100.0	0.0	0.0	289.25	8.5	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

## Folate




QUALAB tolerance : 24 %  
 (< 10.00: +/- 2.40 nmol/l)

Folate (nmol/l)

No. Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1 ADVIA Centaur XP	4	100.0	0.0	0.0	6.86	9.7	e*
2 Cobas E / Elecsys	21	100.0	0.0	0.0	9.95	7.4	e
3 Abbott	10	100.0	0.0	0.0	14.83	11.6	e*

4 additional results were submitted but not published because the method groups were too small. (< results per group)

## Holotranscobalamine




MQ tolerance : 30 %

Holotranscobalamine (pmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	17	88.2	0.0	11.8	104.2	14.5	e
2	Cobas	27	100.0	0.0	0.0	89.5	6.1	e



## Bilirubin total Neo




QUALAB tolerance : 18 %

Bilirubin total Neo (µmol/l)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	15	100.0	0.0	0.0	246	4.0	e
2	Dimension	5	100.0	0.0	0.0	287	4.2	e


## Bilirubin direct



No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	19	100.0	0.0	0.0	124	6.9	a

3 additional results were submitted but not published because the method groups were too small. (< results per group)

## Bilirubin neonatal




QUALAB tolerance : 18 %

Bilirubin neonatal (µmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL700/800	11	100.0	0.0	0.0	292	4.3	e
2	Other methods	13	100.0	0.0	0.0	318	3.5	e

# PSA




QUALAB tolerance : 21 %

PSA (µg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas E / Elecsys	18	100.0	0.0	0.0	8.77	5.6	e
2	Abbott	7	100.0	0.0	0.0	8.06	6.7	e*
3	AFIAS	13	100.0	0.0	0.0	8.92	6.7	e

10 additional results were submitted but not published because the method groups were too small. (< results per group)

### free PSA



QUALAB tolerance : 21 %


free PSA (µg/l)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas E / Elecsys	10	100.0	0.0	0.0	2.37	3.9	e
2	ADVIA Centaur XP/CP	4	100.0	0.0	0.0	2.67	15.8	e*
3	Abbott	5	100.0	0.0	0.0	2.78	5.9	e*

2 additional results were submitted but not published because the method groups were too small. (< results per group)

# K14 Tumor Markers

## CEA




QUALAB tolerance : 21 %

CEA (µg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas E / Elecsys	12	100.0	0.0	0.0	7.6	2.6	e
2	ADVIA Centaur XP/CP	4	100.0	0.0	0.0	8.3	2.6	e
3	Abbott	6	100.0	0.0	0.0	10.4	2.7	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

# CA 125




MQ tolerance : 25 %

CA 125 (kIU/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas E / Elecsys	8	100.0	0.0	0.0	71.5	3.2	e
2	Abbott	5	100.0	0.0	0.0	117.5	4.6	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

## CA 19-9



MQ tolerance : 25 %


CA 19-9 (kIU/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas E / Elecsys	7	100.0	0.0	0.0	16.0	6.1	e
2	ADVIA Centaur XP	4	100.0	0.0	0.0	38.5	13.8	e*

6 additional results were submitted but not published because the method groups were too small. (< results per group)



## CA 15-3




MQ tolerance : 25 %

CA 15-3 (kIU/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas E / Elecsys	10	100.0	0.0	0.0	33.9	3.3	e
2	ADVIA Centaur XP/CP	4	100.0	0.0	0.0	41.9	7.1	e*
3	Abbott	5	100.0	0.0	0.0	42.6	1.7	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

# AFP




QUALAB tolerance : 25 %

AFP (µg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas E / Elecsys	8	100.0	0.0	0.0	89.4	11.4	e*
2	Abbott	4	100.0	0.0	0.0	79.5	4.2	e

6 additional results were submitted but not published because the method groups were too small. (< results per group)

### HCG qn




QUALAB tolerance : 25 %

HCG qn (U/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas E / Elecsys	13	100.0	0.0	0.0	123.7	3.5	e
2	VIDAS	9	100.0	0.0	0.0	50.5	8.8	e
3	Architect	8	100.0	0.0	0.0	124.2	6.9	e
4	AFIAS	6	100.0	0.0	0.0	186.5	8.2	e*

8 additional results were submitted but not published because the method groups were too small. (< results per group)

## HCG intact




QUALAB tolerance : 25 %

HCG intact (U/l)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	4	100.0	0.0	0.0	43.5	1.7	e

One result was submitted but not published because the method group was too small. (< 4 results per group)

# S100




MQ tolerance : 25 %

S100 (µg/l)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	6	100.0	0.0	0.0	1.59	4.1	e

One result was submitted but not published because the method group was too small. (< 4 results per group)

# NSE




MQ tolerance : 25 %

NSE (ng/ml)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	5	100.0	0.0	0.0	3.1	12.9	a

One result was submitted but not published because the method group was too small. (< 4 results per group)

# Thyreoglobulin




MQ tolerance : 25 %

Thyreoglobulin (µg/l)

No. Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1 Cobas	4	100.0	0.0	0.0	79.4	3.6	e
2 Other methods	4	100.0	0.0	0.0	99.2	2.8	e

## CK-MB



MQ tolerance : 30 %


CK-MB (U/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Fuji Dri-Chem	24	100.0	0.0	0.0	39.4	5.3	e
2	Cobas/Roche	7	100.0	0.0	0.0	21.0	3.8	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)



## Cholesterol PTS




QUALAB tolerance : 10 %

Cholesterol PTS (mmol/l)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	CardioChek	14	100.0	0.0	0.0	4.01	32.8	a

## Cholesterol HDL PTS




QUALAB tolerance : 21 %

Cholesterol HDL PTS (mmol/l)

No. Methode	Total	% OK	% insuff.	% outlier	Target	CV% Type
1 CardioChek	14	100.0	0.0	0.0	0.66	16.8 a

# Triglycerides




QUALAB tolerance : 18 %

Triglycerides (mmol/l)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	CardioChek	14	100.0	0.0	0.0	2.79	42.5	a

## C-Peptid




MQ tolerance : 25 %

C-Peptid (nmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	8	100.0	0.0	0.0	1.55	4.3	e
2	Other methods	5	100.0	0.0	0.0	1.27	3.5	e

# ACTH




MQ tolerance : 25 %

ACTH (ng/l)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	8	100.0	0.0	0.0	17.86	9.5	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)


## Procalcitonin



No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	6	100.0	0.0	0.0	3.15	4.2	e
2	Cobas	13	100.0	0.0	0.0	2.13	7.6	e
3	VIDAS	14	100.0	0.0	0.0	1.57	7.4	e
4	Other methods	4	100.0	0.0	0.0	2.39	9.7	e*
5	Liaison	4	100.0	0.0	0.0	4.66	13.9	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

# EPO




MQ tolerance : 25 %

EPO (U/l)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Immulite	4	100.0	0.0	0.0	159.9	16.9	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

## Parathyroid hormone



QUALAB tolerance : 24 %


Parathyroid hormone (pmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas PTH STAT	10	100.0	0.0	0.0	47.1	5.4	e
2	Cobas	10	100.0	0.0	0.0	38.4	4.5	e
3	Abbott	5	100.0	0.0	0.0	89.0	4.1	e

9 additional results were submitted but not published because the method groups were too small. (< results per group)



# Osmolality




QUALAB tolerance : 6 %

Osmolality (mosm/kg)

No. Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1 Cryoskopy	21	95.2	0.0	4.8	323	1.3	e

# Potassium-K22




QUALAB tolerance : 6 %

Potassium-K22 (mmol/l)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ISE	12	100.0	0.0	0.0	3.7	1.4	e

## Sodium-K22




QUALAB tolerance : 6 %

Sodium-K22 (mmol/l)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ISE	12	100.0	0.0	0.0	145	1.2	e

## Glucose-K22




QUALAB tolerance : 9 %

Glucose-K22 (mmol/l)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	12	100.0	0.0	0.0	4.4	2.9	e

## Urea-K22




QUALAB tolerance : 15 %

Urea-K22 (mmol/l)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	12	91.7	8.3	0.0	4.3	7.4	e*

## Osmotic Gap




MQ tolerance : 20 %

Osmotic Gap (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Formel 1 (2Na+K+Glu+	10	90.0	10.0	0.0	21.1	28.8	a

2 additional results were submitted but not published because the method groups were too small. (< results per group)

# Digoxin




QUALAB tolerance : 24 %

Digoxin (nmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Other methods	9	100.0	0.0	0.0	4.66	6.4	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

# Phenytoin




MQ tolerance : 25 %

Phenytoin (µmol/l)

No. Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1 all Participants	4	100.0	0.0	0.0	99	16.5	e*



# Phenobarbital




MQ tolerance : 25 %

Phenobarbital (µmol/l)

No. Methode	Total	% OK	% insuff.	% outlier	Target	CV% Type
1 all Participants	4	100.0	0.0	0.0	239	11.4 e*

# Paracetamol




MQ tolerance : 25 %

Paracetamol (µmol/l)

No. Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1 all Participants	4	100.0	0.0	0.0	685.1	8.1	e*

# Vancomycin




MQ tolerance : 25 %

Vancomycin (µmol/l)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	6	100.0	0.0	0.0	23.2	3.3	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

# Valproat




MQ tolerance : 24 %

Valproat (µmol/l)

No. Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1 all Participants	9	100.0	0.0	0.0	827.0	8.7	e*

# Carbamazepin




MQ tolerance : 24 %

Carbamazepin (µmol/l)

No. Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1 all Participants	5	100.0	0.0	0.0	54.9	5.5	e

# Cystatin C




MQ tolerance : 24 %

Cystatin C (mg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	16	100.0	0.0	0.0	1.14	7.6	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

## Ethanol




QUALAB tolerance : 18 %  
 (< 10.0: +/- 1.8 mmol/l)

Ethanol (mmol/l)

No. Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1 Others	5	80.0	20.0	0.0	8.2	14.2	e*
2 Abbott	7	100.0	0.0	0.0	8.7	8.0	e*
3 Roche, Cobas	19	94.7	5.3	0.0	8.4	7.2	e

# Ammonia



QUALAB tolerance : 21 %


Ammonia (µmol/l)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	4	100.0	0.0	0.0	41.9	10.1	e*
2	all Participants	6	100.0	0.0	0.0	54.7	4.8	e

One result was submitted but not published because the method group was too small. (< 4 results per group)




# Calprotectin



No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Bühlmann fCALturbo	20	85.0	5.0	10.0	99	15.4	e
2	Bühlmann Quantum Blu	5	60.0	0.0	40.0	92	6.9	e
3	Liaison	21	90.5	0.0	9.5	52	16.8	a

6 additional results were submitted but not published because the method groups were too small. (< results per group)

### Cholesterol total Af/b101




QUALAB tolerance : 10 %

Cholesterol total Af/b101 (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas b101	304	99.0	0.0	1.0	3.89	2.6	e
2	Afinion	397	99.2	0.3	0.5	3.91	3.5	e

## Cholesterol HDL Af/b101




QUALAB tolerance : 21 %

Cholesterol HDL Af/b101 (mmol/l)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas b101	301	95.0	0.0	5.0	0.78	3.9	e
2	Afinion	394	92.8	0.3	6.9	0.76	4.7	e

## Tryglycerides Af/b101




QUALAB tolerance : 18 %

Tryglycerides Af/b101 (mmol/l)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas b101	301	98.6	0.7	0.7	1.42	3.0	e
2	Afinion	398	99.7	0.3	0.0	1.35	5.3	e

# Troponin I S




QUALAB tolerance : 24 %

Troponin I S (ng/l)

No. Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1 AFIAS	260	76.2	4.6	19.2	1483.00	12.0	e

## D-dimer qn S




QUALAB tolerance : 21 %

D-dimer qn S (mg/l)

No. Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1 AFIAS	262	81.7	1.9	16.4	0.63	8.7	e

## NT-proBNP S




QUALAB tolerance : 27 %

NT-proBNP S (ng/l)

No. Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1 AFIAS	196	70.4	2.6	27.0	1935.7	12.8	e

# Homocystein




No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Beckman	6	100.0	0.0	0.0	7.6	6.2	e
2	all Participants	4	100.0	0.0	0.0	5.5	6.9	e

One result was submitted but not published because the method group was too small. (< 4 results per group)




# Lipase



No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	10	100.0	0.0	0.0	31.3	6.1	e
2	Beckman	5	100.0	0.0	0.0	31.4	2.1	e
3	Cobas	24	100.0	0.0	0.0	33.9	3.0	e
4	Fuji Dri-Chem	172	98.8	0.0	1.2	40.4	6.1	e

11 additional results were submitted but not published because the method groups were too small. (< results per group)

## Bicarbonat




MQ tolerance : 15 %

Bicarbonat (mmol/l)

No. Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1 Cobas	4	100.0	0.0	0.0	16.2	4.7	e*
2 Other methods	4	100.0	0.0	0.0	15.0	2.7	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

# Cholinesterase




MQ tolerance : 30 %

Cholinesterase (kU/L)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ADVIA Centaur XP/CP	4	100.0	0.0	0.0	6.4	6.0	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

## Glucose CSF




QUALAB tolerance : 9 %  
( < 3.30: +/- 0.30 mmol/l)

Glucose CSF (mmol/l)

No. Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1 Cobas	9	100.0	0.0	0.0	1.70	0.0	e
2 Other methods	12	100.0	0.0	0.0	1.70	4.0	e*

## Lactate CSF




QUALAB tolerance : 18 %

Lactate CSF (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	7	100.0	0.0	0.0	3.80	5.2	e
2	Other methods	10	90.0	0.0	10.0	3.77	2.6	e

## Protein CSF




QUALAB tolerance : 15 %

Protein CSF (g/l)

No. Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1 Cobas	8	100.0	0.0	0.0	0.88	3.8	e
2 Other methods	10	90.0	10.0	0.0	0.85	6.8	e*

One result was submitted but not published because the method group was too small. (< 4 results per group)

## Albumine CSF




MQ tolerance : 20 %

Albumine CSF (mg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	4	100.0	0.0	0.0	315.00	1.9	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)


## CDT



No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Immunoassay	4	100.0	0.0	0.0	1.80	8.5	a
2	all Participants	7	85.7	0.0	14.3	1.45	13.0	a



# Tacrolimus




MQ tolerance : 25 %

Tacrolimus (µg/l)

No. Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1 all Participants	9	100.0	0.0	0.0	13.4	5.6	e

## Totalprotein E




MQ tolerance : 12 %

Totalprotein E (g/l)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	21	95.2	4.8	0.0	75.3	4.9	e

## Albumin E




MQ tolerance : 12 %

Albumin E (%)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Electrophoresis	32	100.0	0.0	0.0	58.5	6.2	e

## alpha-1-Globuline




MQ tolerance : 30 %

alpha-1-Globuline (%)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Electrophoresis	13	100.0	0.0	0.0	2.0	12.7	a
2	capillary electropho	19	94.7	5.3	0.0	3.8	11.0	e

## alpha-2-Globuline




MQ tolerance : 30 %

alpha-2-Globuline (%)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Electrophoresis	32	90.6	6.3	3.1	8.3	15.3	e

## beta-Globuline




MQ tolerance : 30 %

beta-Globuline (%)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Electrophoresis	15	100.0	0.0	0.0	9.4	18.2	a

## Beta-1-Globulin




MQ tolerance : 30 %

Beta-1-Globulin (%)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Electrophoresis	9	100.0	0.0	0.0	6.7	9.1	a


## Beta-2-Globulin



No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Electrophoresis	6	100.0	0.0	0.0	3.4	12.9	a



## gamma-Globuline




MQ tolerance : 30 %

gamma-Globuline (%)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Electrophoresis	8	62.5	12.5	25.0	6.7	20.4	e*

## Gamma-Globuline+P




MQ tolerance : 30 %

Gamma-Globuline+P (%)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Electrophoresis	25	100.0	0.0	0.0	20.4	14.2	e

## Paraprotein




MQ tolerance : 30 %

Paraprotein (%)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Electrophoresis	4	100.0	0.0	0.0	8.1	20.7	a

## Beta-Globuline+P




MQ tolerance : 30 %

Beta-Globuline+P (%)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Electrophoresis	8	100.0	0.0	0.0	26	13.6	e*

## Immundefixation




QUALAB tolerance : 1 %

Immundefixation (Code)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Interpretation	24	100.0	0.0	0.0	2	0.0	e

## Folate in Erythrocytes




MQ tolerance : 40 %

Folate in Erythrocytes (nmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Alinity	5	80.0	0.0	20.0	106	13.0	e*
2	Abbott	7	100.0	0.0	0.0	177	14.8	e*
3	Roche, Cobas	18	100.0	0.0	0.0	1125	9.4	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

## Gallensäure




MQ tolerance : 30 %  
( < 5.0: +/- 1.5 µmol/l)

Gallensäure (µmol/l)

No. Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1 Other methods	7	100.0	0.0	0.0	7.4	20.9	a
2 all Participants	21	100.0	0.0	0.0	5.0	7.4	a

# BNP




QUALAB tolerance : 27 %  
 (< 75.0: +/- 20.0 ng/l)

BNP (ng/l)

No. Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1 Triage	13	84.6	0.0	15.4	21.1	25.3	e*



## Troponin Triage




QUALAB tolerance : 24 %

Troponin Triage (ng/l)


No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Triage high sensitiv	67	92.5	6.0	1.5	612.09	12.9	e
2	Triage SOB/Cardiac	5	20.0	0.0	80.0	20.00	0.0	e
3	Triage Next Gen	10	50.0	0.0	50.0	20.00	0.0	e

## NT-pro BNP



No. Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1 Triage	48	89.5	4.2	6.3	368	13.3	e

## D-dimer Triage




QUALAB tolerance : 21 %

D-dimer Triage (ng/ml)

No. Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1 Triage	74	86.5	8.1	5.4	2363.29	12.1	e

## Vitamin D 25 (OH)




QUALAB tolerance : 27 %

Vitamin D 25 (OH) (nmol/l)

No. Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1 LCMS	4	100.0	0.0	0.0	57.6	12.9	e*
2 Cobas	15	93.3	6.7	0.0	52.9	12.9	e*
3 VIDAS	6	100.0	0.0	0.0	55.3	7.7	e
4 Other methods	11	90.9	0.0	9.1	58.4	15.4	e*
5 Architect	10	100.0	0.0	0.0	54.3	3.9	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

# AMH




MQ tolerance : 25 %

AMH (pmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	18	100.0	0.0	0.0	20.0	5.6	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

# Inhibin B




MQ tolerance : 25 %  
 (< 20.0: +/- 5.0 ng/l)

Inhibin B (ng/l)

No. Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1 all Participants	6	100.0	0.0	0.0	7.7	44.4	e*

# Calcitonin




MQ tolerance : 25 %

Calcitonin (pmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Liaison	5	100.0	0.0	0.0	4.0	2.0	e
2	Other methods	7	100.0	0.0	0.0	11.5	4.1	e

## IGF-BP3




MQ tolerance : 25 %

IGF-BP3 (mg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	4	100.0	0.0	0.0	3.33	1.8	e
2	all Participants	4	100.0	0.0	0.0	3.73	13.2	e*




# Renin



No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Liaison	7	100.0	0.0	0.0	78.0	17.0	a

3 additional results were submitted but not published because the method groups were too small. (< results per group)

## Aldosteron




MQ tolerance : 30 %

Aldosteron (ng/l)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Liaison	4	100.0	0.0	0.0	39.0	16.9	a

2 additional results were submitted but not published because the method groups were too small. (< results per group)


## Anti Thyreoglobulin



No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Phadia	4	100.0	0.0	0.0	105	7.4	e*
2	Alinity	7	100.0	0.0	0.0	24	4.1	e
3	Cobas	9	100.0	0.0	0.0	235	8.8	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

## Anti TPO




QUALAB tolerance : 25 %

Anti TPO (IU/ml)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	11	100.0	0.0	0.0	128	7.1	e
2	Abbott	7	100.0	0.0	0.0	242	5.3	e

6 additional results were submitted but not published because the method groups were too small. (< results per group)

# TRAK




MQ tolerance : 25 %

TRAK (IU/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	6	100.0	0.0	0.0	1.58	9.4	e*
2	Roche, Cobas	7	100.0	0.0	0.0	0.80	6.0	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

## Creatinine WB




QUALAB tolerance : 18 %

Creatinine WB ( $\mu\text{mol/l}$ )

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Statsensor i / Nova	63	69.8	15.9	14.3	95	13.5	a

# IL6




MQ tolerance : 30 %

IL6 (ng/l)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	4	100.0	0.0	0.0	121.0	4.1	e

## Pankreas Elastase




MQ tolerance : 40 %

Pankreas Elastase (ug/g)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Liaison	13	76.9	0.0	23.1	96	15.3	a



# Copeptin




MQ tolerance : 30 %

Copeptin (pmol/l)

No. Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1 Kryptor	6	100.0	0.0	0.0	3.6	8.3	e

## Occult blood qn




MQ tolerance : 30 %

Occult blood qn (ng/ml)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	OC-Sensor	7	85.7	0.0	14.3	443	4.6	e

## Calcium-Urine




MQ tolerance : 9 %  
 (< 2.00: +/- 0.18 mmol/l)

Calcium-Urine (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	13	100.0	0.0	0.0	1.70	2.3	e
2	Abbott	7	100.0	0.0	0.0	1.63	2.3	e
3	Other methods	7	100.0	0.0	0.0	1.67	3.0	e*


## Chloride-Urine



No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	10	100.0	0.0	0.0	98	1.0	e
2	Roche, Cobas	11	100.0	0.0	0.0	91	2.4	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

## Glucose-Urine




QUALAB tolerance : 9 %  
( < 3.3: +/- 0.3 mmol/l)

Glucose-Urine (mmol/l)

No. Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1 Standard chemistry	21	100.0	0.0	0.0	1.5	4.5	e

## Magnesium-Urine




MQ tolerance : 12 %

Magnesium-Urine (mmol/l)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	15	100.0	0.0	0.0	1.68	3.7	e


2 additional results were submitted but not published because the method groups were too small. (< results per group)

## Osmolality-Urine



No. Methode	Total	% OK	% insuff.	% outlier	Target	CV% Type
1 Cryoskopie	19	100.0	0.0	0.0	447	0.7 e

## Phosphate-Urine




MQ tolerance : 15 %

Phosphate-Urine (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	24	95.8	4.2	0.0	8.3	5.2	e



## Potassium-Urine




MQ tolerance : 15 %

Potassium-Urine (mmol/l)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	33	100.0	0.0	0.0	31	1.9	e

## Protein-Urine




QUALAB tolerance : 15 %

Protein-Urine (mg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas/Roche	18	100.0	0.0	0.0	162.9	4.3	e
2	Abbott	14	100.0	0.0	0.0	199.2	2.7	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

## Sodium-Urine



MQ tolerance : 15 %

Sodium-Urine (mmol/l)

No. Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1 all Participants	33	100.0	0.0	0.0	81	2.2	e

## Urea-Urine




MQ tolerance : 15 %

Urea-Urine (mmol/l)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	31	96.8	3.2	0.0	155	7.1	e

## Uric Acid-Urine




MQ tolerance : 15 %

Uric Acid-Urine (mmol/l)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	23	95.7	4.3	0.0	0.67	5.3	e

One result was submitted but not published because the method group was too small. (< 4 results per group)

## Specific Gravity-Urine




MQ tolerance : 5 %

Specific Gravity-Urine ()

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Refractometer	7	100.0	0.0	0.0	1.013	0.2	e

# Ethylglucuronid




MQ tolerance : 25 %

Ethylglucuronid (mg/l)

No. Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1 all Participants	4	100.0	0.0	0.0	0.10	65.4	a

## Creatinine U



QUALAB tolerance : 24 %


Creatinine U (mg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	12	100.0	0.0	0.0	79.8	3.7	e
2	Roche, Cobas	13	100.0	0.0	0.0	74.5	4.8	e
3	Aution	6	50.0	0.0	50.0	80.0	0.0	a
4	AFIAS	17	88.2	5.9	5.9	76.1	11.5	e
5	Afinion	493	94.4	3.0	2.6	73.9	11.5	e
6	Sysmex U	18	50.0	0.0	50.0	82.2	8.1	e
7	Turbidimetry	6	83.3	0.0	16.7	76.3	5.8	e
8	DCA2000/Vantage	119	92.4	1.7	5.9	75.2	7.8	e
9	Siemens Clinitek	25	80.0	0.0	20.0	80.0	0.0	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)



### Creatinin Urin



QUALAB tolerance : 21 %

Creatinin Urin (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	DCA2000/Vantage	117	87.1	2.6	10.3	3.5	7.4	e
2	Afinion	490	98.4	1.2	0.4	3.0	6.1	e
3	Standard chemistry	47	100.0	0.0	0.0	3.2	5.6	e
4	Sysmex U	15	46.7	0.0	53.3	4.4	0.0	e
5	Aution	6	66.7	0.0	33.3	4.4	0.0	a
6	Siemens Clinitek	23	82.6	0.0	17.4	4.4	0.2	e
7	Other methods	4	25.0	0.0	75.0	4.4	0.0	a

2 additional results were submitted but not published because the method groups were too small. (< results per group)